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Abstract. 
 
The response of leukaemia cells to therapeutic agents includes cell cycle arrest and 
apoptosis. The former response is useful in retarding disease progression, but 
induction of the latter is essential for disease eradication. Cell death is often related to 
toxicity so reducing drug-concentration or sensitising target cells to apoptosis is 
desirable. The relationship between the cell cycle and cell death has been at the centre 
of recent investigation focusing on mechanisms of cell death that are not driven 
directly by apoptotic responses. These mechanisms included mitotic catastrophe and 
mitotic slippage. 
The K562 myeloid leukaemia cell line exhibits a combination of p53 negativity and 
carries the Bcr-Abl t (9:22) Philadelphia chromosome. Bcr-Abl is a powerful anti-
apoptotic translocation and is the hallmark of chronic myeloid leukaemia (CML). The 
absence of p53-mediated apoptosis and the anti-apoptotic effects of Bcr-abl delays 
drug-induced cell death, leaving a window of opportunity to investigate the effects of 
different agents on leukaemia cells.  
My investigations show that when DNA-targeting agents are used against myeloid 
leukaemia cells, G2 cell cycle arrest and apoptosis do not occur together i.e. cell cycle 
arrest precludes cell death; cells may escape G2 arrest as a result of mitotic slippage. 
In contrast, when anti-mitotic agents are used, it is necessary to induce mitotic arrest 
to subsequently induce apoptosis; thus lower concentrations are more effective in 
inducing apoptosis than higher drug concentrations. Evidence is provided suggesting 
reduced concentrations of both genotoxic agents and anti-mitotic agents may share a 
common pathway in inducing cell death that is related to events at mitosis and I 
suggest that this pathway has potential for exploitation by new agents currently in 
clinical trials, such as UCN-01, Purvanol, Roscovitine and agents that target the 
passenger proteins, in reducing the concentration of more conventional agents 
required to kill the Bcr-Abl positive leukaemias. 
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1.1 Cell cycle:  
Somatic cells divide into two daughter cells by means of an orderly sequence of 
events called the cell cycle. Resting cells, in the presence of a mitogen, enter the cell 
cycle; they pass through interphase, which includes phases G1, G2, and S phase, and 
enter mitosis where they divide into two daughter cells. The process requires a range 
of factors including work load, growth factors, cytokines and hormones (Murray et al, 
1992). 
Non-cycling cells at G0 phase first enter the cell cycle at G1-phase where the protein 
synthesis needed for the cell growth increases. The cytoplasm expands and the cell 
organelles are reproduced. Normally, G1 phase is followed by S phase where DNA 
replication occurs, and the cell leaves this phase with doubled chromosomes to enter 
G2 phase which is a gap between DNA synthesis and mitosis (Cortz et al, 1997). 
During G2 phase regulatory molecules such as kinases are synthesised. These are 
enzymes needed for protein phosphorylation during mitosis. At the same time, the cell 
continues to grow and to produce proteins needed for the next step which is mitosis or 
M phase. Here, protein synthesis stops and the cell divides into two similar daughter 
cells (Clarke et al, 2006). The duration of mitosis is shorter than interphase. These 
events are summarised in (Figure 1.1). After completion of the cell cycle the cell may 
return to the G0-phase where the cell leaves the cycle, and stops dividing or re-enter 
the cell cycle and continue to proliferate (Voorhees et al, 1976). 
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1.1.1 Key regulatory molecules: 
1.1.1.1 Cyclins: 
 Progression throughout the cell cycle depends largely on the activity of a group of 
kinases, which control the activity of various regulatory proteins by phosphorylation 
and dephosphorylation. These activities are coordinated by associations between 
cyclins and their partner enzymes, cyclin dependent kinases. After binding with 
kinases cyclin activity is altered by phosphorylation, dephosphorylation and 
degradation.  
 The various cyclins are synthesised and degraded rapidly at different and specific 
times of the cell cycle (Figure 1.1) In addition to cell cycle progression, cyclin gene 
expression also controls DNA synthesis (Obaya et al, 2002). 
 
1.1.1.2 Cyclin Dependent Kinases 
There are large numbers of kinases which have different roles and actions during 
different phases of the cell cycle. Each kinase binds with a partner cyclin to form 
complexes which alter the activity of each other. The changing presence of these 
various complexes implies specific functions at each phase in the cycle. Also, 
intracellular levels of the various complexes fluctuate during the cell cycle, thus they 
appear to function at different stages of the cell cycle. (Morgan et al, 1995). 
 
 
 
Najood Omar   14
1.1.1.3 P53 gene: 
DNA damage activates the ATM (Ataxia Telengectasia Mutated gene) which slows 
the rate of cell growth to allow damaged DNA to be repaired. Simultaneously, ATM 
activates DNA-PK. Both of these proteins stimulate transcription of p53, a key protein 
which prevents a mutated cell from progressing through the cell cycle (Hofmann et al, 
2001). Thus p53 acts as a tumour suppressor gene (Casenghi et al, 1999). 
 Stress associated signals received by the cell also activate the p53 gene, and cause 
stabilization of p53 protein. Both mechanisms increase the cellular level of p53 which 
inhibits cell growth. Other signals received from the p53 gene can also cause cell 
cycle arrest at G1 phase thus p53 helps the cell to repair damage after genotoxic 
insults, and this repair enables the cell to pass through a normal cell cycle.  P53 also 
acts as a transcription factor, and can control the transcription of p21, Bax and ∞14-3-
3 (Keeshan et al, 2002).  Dysfunction of these genes frequently results from a p53 
gene stop or point mutation or from a defect in gene transcription, causing loss of p53 
function. The regulation of p53 is complex due to its multiple interconnections and 
the wide range of its functional modifications which include both phosphorylation and 
acetylation (Vousden et al, 2002).  P53 transcription is promoted directly by p300 or 
indirectly by ∞∞14-3-3. P53 transcription is inhibited by PRAP, RPA and Mdm2. 
Mdm2 binds to the N-terminal of p53 by phosphorylation which is carried out by 
Chk1/2 at ser-18 or ser-20 to form a stable complex. The negative feedback loop of 
Mdm2 –p53 regulation results in cleavage of Mdm2 by caspase 3(Villunger et al, 
2003).   
 p53 is transported from the nucleus to the cytoplasm under the control of import and 
export signals. In the cytoplasm, p53 is degraded by its control enzyme E3 ubiquitin 
ligase an APC/C protein. 
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The importance of p53, the ‘guardian of the genome’, in monitoring DNA damage and 
control of the cell cycle makes it a crucial tumour suppressor gene and p53 mutations 
are an important event in carcinogenesis for many tumours(Clifford et al, 2003). 
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                                Cell cycle regulation 
           
 
 
 
 
 
 
 
 
 
 
Figure 1.1: 
The main cyclins and cyclin dependent kinases and their inhibitors involved in the 
regulation of cell cycle in each phase of the cell cycle (Modified from Golias et al, 
2004). 
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1.2  Control of the cell cycle : 
1.2.1 Entry into the cell cycle G0 to G1-phase. 
Cells will enter the cell cycle in the presence of a mitogen. Cyclin D is the dominant 
cyclin in this phase. Cyclin D synthesis is induced as the cell leaves quiescence to 
enter the first gap phase of the cell cycle. It forms an activated complex by binding to 
CDK4 or 6. Formation of these complexes not only stimulates the cell to enter the cell 
cycle, but the action of these complexes must be sustained for progression through the 
cell cycle. (McGowan et al, 2003).                                                                                
1.2.2 G1 phase: 
Transition through G1 requires continued cyclin D/CDK4/6 activity. Towards the end 
of G1, cyclin E is synthesised and this binds to CDK2 to form an active complex that 
takes cells through to the end of G1 (Voorhees et al, 1976). 
1.2.3 G1-S transition: 
Cyclin E/CDK2 complex interacts with E2F family of cell cycle transcription factors 
to activate transcription of proteins needed at G1-S phase. This is important for full 
activation of the S-phase transcription programme. Cyclin A synthesis begins at the 
G1-S boundary and cyclin E/CDK2 activity reaches its peak at mid S-phase. Cyclin A 
gradually down regulates cyclin E by phosphorylation, which allows its recognition 
by the proteosome. This destroys cyclin E which helps to initiate DNA replication and 
prepares the cell for S phase (Cortez et al, 1997). 
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1.2.4 S Phase: 
 In parallel with the degradation of cyclin E|CDK2 complexes, cyclin A is expressed 
simultaneously and forms cyclin A/CDK2 complexes. Cyclin A/CDK2 complexes are 
important for the completion of DNA replication (Obay et al, 2002). The activity of 
these complexes is down regulated by dephosphorylation after binding to E2F. This 
effect completes S phase and allows progression to the next phase, mitosis (Boye et al, 
2008). 
1.2.5 G2 phase: 
Throughout interphase cyclin B/Cdk1 remains inactive by inhibitory phosphorylation 
of the cyclinB|Cdk1 complex due to phosphorylation of Cdk1 at threonine-14 by Myt-
1 and at tyrosine-15 by Wee1. Activation of the complex by threonine-161 
phosphorylation also occurs but the complex remains inactive until the final activation 
step.  At the end of G2 this drives the cell to mitosis by dephosphorylation of 
threonine 14 and tyrosine 15 by Cdc25 phosphatase which is regulated by cyclinB-
Cdk1 itself and by Plk1 during mitosis (Hutchins et al, 2004). (Figure 1.2)(Figure 1.3) 
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                                Activation of cyclin B/Cdk1 complex 
 
G2 to Mitosis
Myt1  CAK 
Figure 1.2: 
An inactive cyclin B/Cdk1 complex is formed by inhibitory phosphorylation of CDK1 
at threonine-14 and tyrosine-15 during interphase. The complex is activated by 
phosphorylation of Cdk1 threonine-161, then for the final activation step it requires 
dephosphorylation of threonine 14 and tyrosine 15 by Cdc25 phosphatase in mitosis 
(Hutchins  et al, 2003). 
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1.2.6  Mitosis: 
Conventionally, mitosis is divided into prophase, prometaphase, metaphase then 
anaphase, telophase and cytokinesis. In prophase, nuclear chromatin becomes tightly 
coiled and condensed and DNA coiling allows chromosomes to become prominent.  
The nucleolus is lost early in mitosis. In the cytoplasm the centrioles of the mitotic 
spindle move to the cell poles and microtubules extend from each centeriole (Oegema 
et al, 2006). 
 In prometaphase, fragmentation of the nuclear membrane is followed by growth and 
migration of microtubules from the centrioles. Microtubules extend towards the centre 
of the cell, where they  attach to chromosome centromeres on the sister chromatids via 
the kinetochores (Zachariae et al, 1999).  Kinetochores are highly complex protein 
structures that congregate on the spindle side of centromeres of each chromosome. The 
kinetochores of each sister chromatid must interact with the microtubules that 
originate from opposite spindle poles, to ensure equal separation of the genetic 
material. When the cell begins to divide tension created by contraction of the attached 
microtubules will cause the chromosomes to start moving apart (Alberghina et al, 
1975). 
In metaphase, the metaphase plate forms in the centre of the dividing cell.  The 
chromosomes are aligned in relation to the metaphase plate by the spindle fibres, which 
are now attached to the kinatochores of the centromeres. Each sister chromatid is 
attached to spindle fibres originating from the opposite pole. At this stage the spindle 
apparatus is fully formed with each centeriole now placed on opposite poles of the cell 
(McGowan et al, 2003).  
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In anaphase, the paired chromosomes are pulled to opposite sides of the cell. This is 
brought about by formation of the central spindle mid-zone. Shortening of the spindle 
microtubules pulls on the kinetochores and the chromosomes move to the opposite ends 
of the cell (Harper et al, 2002).   
Telophase is the last phase (Figure 1.4). The chromosomes uncoil and become less 
condensed, and the spindle apparatus disappears.  Two daughter nuclei start to develop 
nuclear membranes. Mid-bodies form, connecting the two daughter cells, while each is 
surrounded by newly synthesised cytoplasmic membranes (Altieri et al, 2003).  
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                         G2M Checkpoint activation 
 
Figure 1.3: 
In response to DNA damage p53 is responsible for increases in the synthesis of the 
Cdk1 (cdc2) inhibitor p21 and ∞∞14-3-3 proteins. The result is a complex interaction 
of proteins to bring about cell cycle arrest at the transition from G2 to mitosis 
(O’Connor et al, 2000) 
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1.2.7 Cytokinesis: 
After mitosis cytokinesis is synchronized with nuclear partition. Cytoplasmic division 
starts at the completion of chromosome segregation. First, in the outer cytoplasmic 
membrane a cleavage furrow forms a ring at the level of the old metaphase plate.  The 
ring contains actin and myosin filaments and their contraction initiates the splitting 
into two daughter cells (Altieri et al, 2001).  
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Cytokinesis. 
 
 
Figure 1.4: 
 Stages of mitosis showing the components required: kinetochores, centrosomes, 
spindle microtubules, central spindle mid-zone and mid-bodies (Altieri et al, 2001). 
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1.3     Cell cycle checkpoints: 
These constitute a control system which monitors the orderly progression through the 
phases of the cell cycle. Cell cycle checkpoints have internal and external controls to 
direct the timing and order of critical events by a system of checkpoint signalling.  A 
problem in any of the cell cycle pathways can produce stop signals which inhibit the 
operation of all other pathways and retard cell cycle advancement. Sometimes, in the 
presence of genomic instability, checkpoint signalling fails to respond to cellular 
defects. This is one of the mechanisms that predisposes to cancer (Kastan et al, 2004). 
1.3.1  G1/S-phase or the DNA damage checkpoint: 
 The first checkpoint is at the G1/S-phase border. Of the various control systems, the 
most important is p53 and its antagonist Mdm-2.  Phosphorylation of Mdm-2 activates 
and stabilizes p53 which allows p21 gene transcription. In response to DNA damage, 
p21 inhibits cyclin A/CDK 2, cyclin E/CDK2 complexes and therefore arrests the cell 
at G1 phase (McGowan et al, 2003).  
1.3.2   G2 DNA damage checkpoint:    
Detection of DNA damage stimulates two responses: one is the repair of the damaged 
DNA itself, and the other is creation of enough time for DNA repair by delaying cell 
cycle progression. This delay is achieved by down regulation of cyclin dependent 
kinase activity (Figure 1.2). Inhibition of kinases prevents the cell cycle progressing to 
mitosis by activation of Chk1 which indirectly inhibits Cdk1 (Damelin et al, 2007). 
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1.3.4  G2M checkpoint: 
This is controlled mainly by phosphorylation of the dominant kinase which forms 
cyclin B/Cdk 1 complex. Cyclin B/Cdk1 complex is known as the maturation 
promoting factor (MPF). The Myt1 and Wee1 kinase  phosphorylates threonine 14 
and tyrosine15 on Cdk1 throughout interphase. The Cdk1/cyclin B complex is then 
activated by Cdc-25 which dephosphorylates tyrosine 15 and threonine 14 at the end 
of G2 and through mitosis  (Nurse 1990)(Cummings et al, 2002). p53-mediated 
transduction of p21 may also target this checkpoint by directly inhibiting  the cyclin 
B/Cdk1 complex (Figure 1.3) 
However, following DNA damage cyclin B/Cdk1 complex can be inhibited by the 
sequestration of Cdc25 which is bound to ∞∞14-3-3 which in turn is  activated by 
Chk-1&2 via ATM/ATR(Morgan et al, 1995).  
Un-replicated or damaged DNA keeps the cyclin B/Cdk1 complex inactive. This is a 
mechanism that leads to cell cycle arrest at G2 phase (Smits et al, 2001).  
1.3.5  Spindle assembly checkpoint:  
After DNA duplication the chromosomes consist of pairs of sister chromatids joined 
by complexes of proteins known as cohesin.  During mitosis the pairs must be pulled 
apart by the mitotic spindle fibres which shorten from their kinetochore end (Taylor et 
al, 2007).  
The spindle assembly check point is regarded as bipartite:  one arm monitors 
kinetochore occupancy by microtubules and the other arm monitors the spindle 
tension applied to the kinetochores (Adams et al, 2003). 
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The main protein components of the spindle assembly checkpoint are Bub1, BubR1, 
Mad1 and Mad2. In early mitosis BubR1, Mad-1 and Mad-2 are all located on the 
kinetochores, while BubR1 is essential to the spindle assembly checkpoint (Vogt et al, 
2008). Activation of these proteins in response to spindle damage arrests mitosis in 
metaphase. They activate APC/C by inhibition of the action of Mad-2 after binding 
with Mad-1 where they form an inhibitory complex with Cdc-20 (Vogel et al, 2004).  
Cdc-20 is the key activator of APC/C by Mad2-Cdc20. Mad2-Cdc20 complex 
generates an anaphase stop signal to allow correct arrangement of the chromosomes 
via their kinetochores and the microtubule spindle apparatus. 
BubR1 is the connection between the kinetochore microtubule interaction and the 
APC/C. The activity of BubR1 is regulated by CENP-E which binds to it and targets it 
to its position in the kinetochores (Morrow et al, 2005). 
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1.4 Anaphase Promoting Complex/Cyclosome (APC/C):  
The anaphase promoting complex (APC/C) is essential for the progression of the cell 
through the early phases of mitosis and its exit  from anaphase into telophase. The 
APC/C is a multi-protein complex consisting of eleven subunits: Apc1, Apc2, 
Apc3/Cdc27, Apc4, Apc5, Apc6/Cdc16, Apc7, Apc8/Cdc23, Apc10/Doc, Apc11 and 
Apc13 (Kumar  et al, 2005). 
APC/C uses two co-activators: the first, Cdc20, operates in early mitosis and then 
Cdh1/Hct1 acts in late mitosis to help progression to anaphase. The activity of the 
APC/C complex is regulated by phosphorylation. The phosphorylation is controlled 
by Polo like kinase-1 (PLK1) which works in harmony with the mitosis promoting 
factor cyclin B/Cdk1 complex.  
The cyclin B/Cdk1 complex also activates the APC/C complex. Since cell cycle 
progression also requires controlled degradation of regulatory proteins, protein kinase 
A (PKA) modifies and inhibits the complex (Plyte et al, 2007). 
1.4.1 APC/C at mitosis: 
The catalytic activity of the APC/C complex is controlled by a protein called the early 
mitotic inhibitor 1 (Emi1). Emi1 is phosphorylated by PLK1 during prophase, causing 
its inactivation or destruction throughout pro-metaphase. This allows dissociated Cdc-
20 to conjugate with APC/C. Inhibition of this process is achieved by Rassf1A. At the 
end of pro-metaphase, APC/C, associated with its cofactor Cdc20 becomes active in 
degrading proteins such as cyclin-A which will later disappear in metaphase. Further 
progression of the cell to anaphase is induced by the degradation of cyclin B by 
APC/C –Cdc20, and destruction of securin, PLK1 and Aurora B by APC/C –Cdh1 
during late mitosis (Gladfelter et al, 2006). 
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1.4.2  APC/C at spindle assembly checkpoint: 
The spindle assembly checkpoint is turned on by unattached kinetochores which 
stimulate the spindle assembly attached proteins including Bub1, BubR1, Bub3, 
Mad1, and Mad2. These proteins produce the anaphase stop signal that inhibits 
APC/C-Cdc20 (Morrow et al, 2005). This creates time for the unattached kinetochores 
to take their place on the centromeres. When the repair is finished, the properly placed 
kinetochores-associated proteins will revert to their original places. Inhibitory signals 
to APC/C-Cdc20 complex will stop and thus its activity is retained. This helps the cell 
to progress through, and out of, anaphase (Baker et al, 2007) (Figure 1.5).  
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Regulation of APC/C 
 
 
 
  
 
 
 
 
 
 
Figure 1.5: 
Regulation of APC/C at the mitotic checkpoint in early mitosis, prometaphase 
/metaphase and regulation of mitosis stimulating and inhibitor factors (Baker et al, 
2007). 
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1.5  Cell death: 
Cell death occurs in different ways: these include apoptosis, mitotic catastrophe and 
necrosis. Each form of cell death has different morphological and biochemical 
manifestations.  
Apoptosis is known as programmed cell death. It is associated with specific enzymatic 
reactions before the cell dies. Electrophoresis of DNA extracted from apoptotic cells 
shows a characteristic ladder formation on gels indicating fragmentation due to the 
action of endonucleases (Taylor et al, 2000).  
Mitotic catastrophe is due to complete failure of mitosis. It is characterised by 
multipolar mitotic figures showing many uncondensed chromosomes contained within 
large cells.  Mitotic catastrophe is then often followed by apoptosis (Roninson et al, 
2001). 
Necrosis follows direct damage to the cell. Often contiguous cells or sheets of cells 
are involved. Such necrosis is often followed by a characteristic inflammatory 
response after cell membrane and nuclear destruction (Castedo et al, 2004). 
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1.5.1  Apoptosis: 
Apoptosis, also has specific morphological features. These include loss of attachment 
of the cell membrane, cell shrinkage, nuclear and chromosomal fragmentation, 
chromatin condensation, cellular blobbing and budding and fragmentation. Eventually 
cell fragments give rise to characteristic apoptotic bodies which will eventually be 
phagocytosed by macrophages or adjacent cells without damage to the surrounding 
cells or an inflammatory reaction (Taylor et al, 2000).  
1.5.2 Caspase activation: 
Factors involved in apoptosis include cascades of caspase enzymes which are cysteine 
proteases. Proteolytic cleavage causes zymogen dimerization.  Normal precursors 
contain an N-terminal prodomain with small and large destruction sub units which are 
activated by cleavage at aspartate residues. Activation of the caspase cascade via the 
initiator caspases 8 and 9, via death receptors, via formation of an apoptosome or 
other modes of action, activate effecter caspases such as caspase 3, 6 and 7 (Shi. et al, 
2002).  The effecter caspases  must be cleaved by the initiator caspases 8-9. (Boatright 
et al, 2003). 
There are two pathways of apoptosis activation: intrinsic and extrinsic. Intrinsic or 
stress pathway activation begins by the formation of the apoptosome. This is a 
complex of Apaf-1, pro-caspase 9, ATP and cytochrome C; the latter being released 
after mitochondrial membrane responses to Bax, Bak and Bcl-2 interactions. Bcl-2 is 
an antiapoptotic protein released from the endoplasmic reticulum (Thomadaki et al, 
2006). This controls Bax and/or Bak activation. Bax and Bak are pro-apoptotic 
proteins which participate in the release of cytochrome C (Garrido et al, 2006) (Figure 
1.6). 
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The extrinsic pathway operates mainly through the ‘death receptors’ in the 
cytoplasmic membrane via the adaptor protein FADD (fas –associated death domain) 
CD95 or tumour necrosis factor receptors 1 and 2 (TNFR1&2) via the adaptor protein 
TRADD (Figure 1.7). Other receptor mechanisms include TRAIL. These receptors 
stimulate aggregation and activation of caspase 8 and the downstream caspase 
cascade, especially caspase 3, will then be stimulated (Spierings et al, 2005). This 
pathway can lead to apoptosis without involvement of mitochondria (Elmore et al, 
2007). 
 In some cell types such as hepatocytes the death receptor associated caspase-8 is 
insufficient to activate downstream caspases, so in this case, caspase-8 acts by 
cleaving Bid (Bcl-2 homology-3 containing protein) to form tBid, which stimulates 
mitochondrial release of cytochrome-C and hence the activation of downstream 
pathway (Fulda  et al, 2006). 
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1.5.3 The Role of Mitochondria: 
Mitochondria are essential for cellular metabolism. The archetypal function of 
mitochondria is the production of adenosine triphosphate (ATP) which is 
accomplished by oxidative phosphorylation and the respiratory chain. Mitochondria 
are crucial for metabolism of carbohydrates, fatty acids and amino acids. However 
mitochondria also regulate cell death and play a significant role in apoptosis. 
Mitochondria contain several active proteins such as cytochrome C, apoptosis 
inducing factor (AIF), endonuclease G, and Smac /Diablo (Madesh et al, 2002).  The 
release of these proteins activates the caspase cascades, while translocation of AIF to 
the nucleus also stimulates apoptosis via a caspase independent pathway (Garrido et 
al, 2006). 
The Bcl-2 family of proteins increase the permeability of the mitochondrial 
membranes. Bax or Bak are essential for the permeability process as both can 
oligomerise to form pores in the mitochondrial outer membrane. Uptake of water 
causes swelling and rupture of mitochondrial membranes enhancing the release of 
mitochondrial proteins essential for apoptosis. Anti-apoptotic  proteins e.g. Bcl-2, 
Bcl-XL can negate the effects of Bax and Bak by heterodimerisation thus preventing 
mitochondrial-dependent apoptosis. De-repression of anti-apoptotic proteins by other 
Bcl-2 family proteins such as Puma and Noxa, however, can negate anti-apoptotic 
proteins thus bringing another layer of control of cytochrome C release. (Caroppi et 
al, 2009). 
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Mitochondrial apoptosome 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.6:  
The death promoting members of Bcl-2 (Bid, Bax, Bad, Bak, and Bik) are induced in 
response to stress and take their places within mitochondrial membrane. This triggers 
the release of cytochrome c which can be blocked by death inhibitory members of the 
Bcl-2 family (Bcl-2, Bcl-XL). Binding of cytochrome c to Apaf-1 promotes binding 
with caspase 9 to form a complex resulting in the activation of caspase 9 which then 
directly activates caspase 3, 6 and 7 resulting in cellular destruction.(Modified from 
the mitochondrial apoptosome (Martines, et al 2001). 
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1.5.4 Mitotic catastrophe:  
This type of cell death is caused by mitotic failure due to failure of chromatin 
condensation or damage to the spindle formation (Vakifahmetoglu et al, 2008). The 
morphological features include chromatin condensation and micro nucleation of the 
cell. Many factors predispose to mitotic catastrophe: these include p53 gene which 
regulates the G1 checkpoint, cyclin-B/Cdk1, aurora kinase and survivin (Castedo et al, 
2004). 
In p53 deficient cells caused by mutation, mitotic catastrophe can follow failed 
mitosis with no apparent apoptosis.  p53 mutated cells are resistant to cell death 
following genotoxic insults caused by chemotherapeutic drugs. Microtubule 
depolymerising agents and DNA damaging agents induce premature mitosis without 
checkpoint activation and this predisposes to mitotic catastrophe (Smith et al, 2001).  
Activation of CyclinB/Cdk1 complex requires many control steps and is important in 
the induction of mitosis and chromatin condensation. DNA damage stimulates 
checkpoints which in turn activate kinases such as Wee1/Myt1 and Chk1, and Chk2 to 
stop progression to mitosis by inhibiting Cdk1. Similarly, inhibition of APC stops 
degradation of cyclin-B at the spindle assembly checkpoint. Therefore any aberrant 
entry to mitosis in the presence of incomplete DNA replication causes mitotic 
catastrophe (Hoffmann et al, 2001). 
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1.6  Mitotic slippage: 
Mitotic slippage, also known as checkpoint adaptation, is an escape from mitosis in 
spite of normal levels of factors controlling the spindle assembly checkpoint 
(Musacchio et al, 2007). In human cells slippage is usually associated with cyclin B 
destruction (Taylor et al, 2007).  
When the signals from spindle fibers are abnormal or absent, kinetochores release 
Mad2 which binds to Cdc20 and dissociates it from APC/C; this deactivates APC/C 
and prevents destruction of securin which accumulates and prevents the action of 
separase.  This creates more time for the cell to correct its situation. APC/C activation 
achieved by association with Cdc20 inhibits cyclin-B/Cdk1 complex activity at 
mitosis by proteolytic cleavage of cyclin-B. This allows a cell to escape mitosis with 
an incomplete spindle assembly checkpoint. 
The spindle assembly checkpoint delays the exit of a cell with inadequately attached 
kinetochores from mitosis. There is destruction of cyclin B by APC/C proteolysis. 
This inhibits cyclin B/Cdk1 activity and allows the cell to escape mitosis in the 
presence of an incompletely active spindle assembly checkpoint (Herzog et al, 2009). 
Other opinions suggest that depletion or lack of accumulation of active chromosomal 
passenger complex in centromeres at mitosis might lead to premature mitotic exit 
accompanied by the loss of Mad2 and Bub1 from unattached kinetochores (Stoepel et 
al, 2005). 
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1.7 Chromosomal passenger complex: 
The chromosomal passenger complex refers to  a number of proteins that change their 
location throughout mitosis. So far, six chromosomal passenger proteins have been 
isolated from human cells. These consist of INCENP (inner centromere protein), Aurora 
B, Borealine /Darsa B, survivin, CSC-1 and TD-60 (Vagnarelli et al, 2004). 
 The chromosomal passenger complex is usually localized to inner centromeres. 
However they can change their position as the cell passes through metaphase to 
anaphase. They move to the mid-zone of the spindle apparatus during anaphase, and 
finally they localize to the mid-body during telophase. Diminution of any one of the 
chromosomal passenger constituents by any means triggers the elimination and 
mislocalization of the others (Caravalho et al, 2003). 
1.7.1  Function of chromosomal passenger complex: 
The chromosomal passenger complex contributes to chromosome organization, 
tension sensing, BubR1 and Mad2 targeting and microtubule dynamics. It is necessary 
to sustain spindle checkpoint activity (Terada et al, 2001). The role of Aurora B at the 
spindle assembly checkpoint, as part of the chromosomal passenger complex, is to 
arrest the cell cycle temporarily to prevent the tension between the kinetochores. 
Aurora B can detect and stabilize faulty attachments of microtubules to the 
kinetochore. It regenerates unattached kinetochores that are detected by the spindle 
assembly checkpoint, particularly when cells are under stress such as caused by drugs 
that affect the kinetochores (Lens SM et al 2006). The chromosomal passenger 
complex indirectly inhibits APC/C. However, they allow the cell to transmit lack of 
tension back to the attached microtubules (Gassmann et al, 2004). 
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 In prophase the chromosomal passenger complex helps in kinase activation. During 
anaphase, the chromosomal passenger complex acts on spindle structure and stability. 
It targets MKLP1, and contributes to cytokinesis (Lens et al, 2003). 
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1.7.2  Survivin: 
Survivin is a highly conserved intracellular protein of 70 amino acids and a molecular 
weight of 16.5 kDa. (Yigong Shi et al 2000). There are three splice variants known as 
survivin, survivin- 2B and survivin- Dex3 (Li et al, 2003). Survivin is produced 
mainly at G2M phase of the cell cycle (Kasof et al, 2001). Survivin has a long C-
terminal helix motif zinc-coordinating Cys/His at the terminal half of the protein that 
interacts with polymerized microtubules and homodimerizes in solutions (Altieri et al, 
2006).  
  It is a known member of the inhibitor of apoptosis (IAP) gene family whose 
members include: NAIP, cIAP1, cIAP2, XIAP, S-XIAP, ML-IAP, Apollon and 
survivin. Not all of the IAP family members are cell death inhibitors. The IAP 
proteins are inhibited by the mitochondrial protein Smac (Wei et al, 2008) (Figure 
1.7) 
Survivin contains only one BIR domain which is consistent with a potential role in 
inhibiting the apoptotic pathway at the level of caspase 3 and 7 but not 8 (Kaufmann 
et al, 2001). Survivin acts  downstream of the Bax signaling pathway to inhibit 
apoptosis. Survivin is highly expressed in foetal tissue and in the majority of tumours, 
but not in normal adult tissue (Altieri et al, 1999). Its presence in high levels in 
tumours is associated with a poor patient prognosis, due to advanced cancer 
progression, high recurrence rate, drug resistance and short survival rate (Reed et al, 
2001). This function of survivin is separate to its function as a passenger protein. 
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 The IAPs 
Figure 1.7: 
 The IAPs including survivin are able to inhibit caspases 9 and 3. This ability can be 
stopped by release of Smac a mitochondrial protein. This allows the completion of 
apoptosis. (Modified from Altieri et al, 2001). 
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1.7.5 Localization of survivin as a passenger protein 
During mitosis survivin is associated with the microtubules of the mitotic spindle 
(Alteiri et al, 2000). This forms the chromosomal passenger complex with INCENP 
(inner centromere-binding protein) and Aurora B kinase (Sessa et al, 2005). Survivin 
was detected in MCF-7E breast cancer cells at G1/S where it blocks vitamin D3, 
allowing G1 arrest and resulting in accumulation of cells in S and G2M phases. (Li  et 
al, 2006). 
1.7.6 Function: 
In dividing cells survivin regulates mitosis (Lens et al, 2006Dec). It also inhibits 
apoptosis. Survivin begins its anti apoptotic role by being activated by 
phosphorylation at threonine 34 by CDK1-cyclin B complex which is a mitotic 
kinase, this process is associated with sequestration of caspase 9 
Survivin also plays a role in mitosis and microtubule function (Altieri et al, 2004). 
Survivin and the inner centromere protein INCENP show similar cell cycle 
localization and gene knockout phenotypes.  From late prophase until metaphase they 
are localised at centromeres while at anaphase they localize to the mitotic spindle 
mid-zone. Later in anaphase and in telophase, survivin is localised with the 
microtubules (Wheatley et al, 2005). 
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1.7.3  Aurora B kinase: 
Aurora B kinase is one of three serine/threonine protein kinases A, B and C that 
regulate pathways of cell division. Aurora B kinase is another chromosomal passenger 
protein that is involved in a number of processes during mitosis (Vader et al, 2006). In 
proliferating tissues Aurora B expression and activity is cell cycle dependent. Its 
concentration peaks at G2M transition and the kinase activity is highest at mitosis. 
Aurora B is phosphorylated by CDK activity and localizes at centromeres throughout 
pro-metaphase. When activated it is responsible for the phosphorylation of histone H3 
serine 10 during mitosis (Murnion et al, 2001). 
Aurora-B is necessary for chromosome condensation. It localizes on kinetochores at the 
cytokinesis phase of the cycle. When spindle tension is disturbed, a spindle assembly 
checkpoint occurs (Andrews et al, 2005).  In the inner centromere Aurora B promotes 
the release of bound microtubules and therefore promotes the formation of monotelic 
attachments where chromosomes become attached to both spindle poles (Taylor  et al 
2004). In p53 deficient cells over expression of Aurora kinase leads to failure of 
cytokinesis and progression of the cell cycle then produces aneuploidy which 
characterises aggressive tumours (Adams et al, 2001). 
1.7.4  Inner centromere protein (INCENP): 
INCENP derives its name from its localization in the inner centromere of chromosomes. 
It consists of 60-80 amino acids near the C terminus of a protein known as the IN-box 
and is consequently phosphorylated here. This phosphorylation improves the activity of 
Aurora B kinase. INCENP is important for chromosomal segregation and cytokinesis 
(Carmena et al, 2003). 
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1.7.5  Borealine/Darsa B: 
Borealine is a 31kda protein which has two related polypeptides called 
Borealine2/DarsaA. In mitotic cells Borealine is associated with survivin and also 
binds to INCENP. Borealine B is required for the chromosomal passenger complex to 
take its place at the centromere (Gassmann et al, 2004). 
It is similar to chromosome segregation and cytokinesis defective-1(CSC-1): CSC-1 is 
a 27-kda protein which has similar function to Borealine. Both have short domains at 
both ends.  Although CSC-1 requires zinc to bind to BIR-1 which is the binding site 
of survivin and INCENP, Borealine B does not need it for its binding to survivin. 
CSC-1 is required to target kinases (Vagnarelli et al, 2004). 
1.7.6  Telophase disk -60 (TD-60): 
Telophase disk -60 is a 60-kDa protein found at the spindle mid-zone and equatorial 
cortex. Borealine-B which is essential for localization of TD-60 at mitosis acts as a  
specific exchange factor for Rac1. TD-60 is essential for the localization of the 
chromosomal passenger complex and for progression of mitosis    (Vagnarelli et al, 
2004). 
A complete understanding of the cell cycle and particularly of crucial checkpoints, 
gives opportunities to design drugs and other strategies for the treatment of human 
tumours. 
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1.8 Chronic Myeloid Leukaemia (CML): 
Leukaemia is a disorder resulting from malignant transformation of the primitive 
haemopoietic stem cell. It can involve both lymphoid and myeloid lineages. The 
WHO classification shows CML as one of seven entities in the category of chronic 
myeloproliferative disease (Vardiman et al, 2002).  
1.8.1 Incidence: 
CML is a disease of all age groups but more common in a middle age (45-55 years) 
with male to female ratio of 2:1. It accounts for 15- 20% of adult leukaemia. It is more 
common in Caucasians.  The incidence is about 1-2 per 100,000 population per year 
(D'Antonio 2005). 
1.8.2 Clinical presentation: 
 Clinically, CML patients have fatigue, weight loss, abdominal fullness, bleeding, 
purpura splenomegaly, leukocytosis, thrombocytosis, and anaemia. The disease 
progresses from a chronic phase, through an accelerated phase, then a terminal blast 
crisis or acute leukemic phase (D'Antonio , 2005). 
1.8.3 Karyotype: 
CML is characterised by a karyotypic abnormality. Invariably there is a chromosomal 
translocation of chromosomes 9 and 22 (t (9; 22)) which creates the “Philadelphia 
chromosome”.  This translocation forms the abnormal BCR/ABL fusion gene which 
is required for the development of 95% all cases of CML (Sattler et al, 1997) (Figure 
1.8),  
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1.8.4 BCR/ABL: 
 Expression of the BCR-ABL gene is found in haematopoietic stem cells (HSCs).  The 
t(9: 22) translocation which forms the Philadelphia chromosome results in a molecular 
rearrangement between the c-ABL proto-oncogene on chromosome 9 and the BCR 
(break point cluster region) on chromosome 22. This forms BCR/ABL fusion gene 
which codes for a p210-KDa protein.  The N–terminal breakpoint cluster region 
(BCR) fuses to the ABL tyrosine kinase (TK) gene causing enhancement and 
activation of the tyrosine kinase (Pear et al, 1998). 
 The BCR/ABL chimeric protein stimulates a range of intra-cellular signalling and 
inhibits apoptosis; these effects can stimulate cell proliferation in the absence of 
growth factors which facilitates tumour progression and metastasis (Pasternak et al, 
1998).  
1.8.5 Action of BCR/ABL: 
The oncogenic activity of BCR/ABL is responsible for the tetramerization of 
BCR/ABL which augments tyrosine kinase activity (Sattler et al, 1997). BCR/ABL 
induces interleukein-4 and 7 production (IL4, IL7), as well as 
granulocyte/macrophage – colony stimulating factor (GM-CSF) (Wetzler et al, 1993). 
As ABL can phosphorylate tyrosine residues the BCR-ABL gene product is also a 
tyrosine kinase. This is a continuously active gene which can stimulate and speed up 
the cell cycle. However there is associated DNA damage as it inhibits DNA repair and 
therefore causes genomic instability (O’Brien et al, 2005). 
BCR/ABL activity results in activation of several downstream pathways: these  include 
the phosphotidylinositol-3 kinase/AKT (PI-3K/AKT) pathway, the single transducer 
and activator of transcription (STAT) pathway and Ras/mitogen-activated protein 
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Interferon alpha (INFα) is a glycoprotein with an anti-proliferative action. It induces a 
therapeutic response in 35-55% of patients. It was an effective therapy for CML and 
was commonly used until the arrival of the Imatinib. Imatinib mesylate is a synthetic 
ATP inhibitor. It competitively inhibits ATP binding to BCR-ABL residues by tyrosine 
phosphorylation and helps its entry to the nucleus so that it loses its antiapoptotic 
functions. This drug has changed the management of CML. It was recently approved as 
a first line treatment of CML at all stages of the disease and a complete cytogenetic 
remission and 5 year survival rates of almost 90% have been achieved (Martinelli et al, 
2005) 
Management of CML varies. Marrow ablation by chemotherapy and allogenic stem cell 
transplant is the only curative therapy. However there are side effects and a significant 
mortality. The degree of histocompatibility between donor and recipient influences a 
marrow transplant performed in the chronic phase of the disease. There is a 6-8% 
chance of recurrent leukaemia at 5 years; however, if performed at the accelerated phase 
the 5 year survival increases to 50%. 
1.8.6 Management: 
kinase (Ras/MAPK) (Cortez et al, 1997). Ras activation leads to phosphorylation and 
activation of MAPK protein signalling pathway which includes extra-cellular signal–
regulated kinase (ERK) and c-jun N terminal kinase (JNK). The MAPK activation 
signals in BCR/ABL lead to enhancement of proliferation and survival signalling 
(Woessmann et al, 2001). The outcome is therefore that myeloid leukemic cells have a 
longer life than normal leukocytes.  
 
WHO Classification pf malignant haematological diseases 
Classification  FAB WHO Comments 
Myeloid malignancies • Chronic myeloproliferative diseases 
• Myelodysplastic syndromes 
• Acute myeloid leukemia 
 
• Chronic myeloproliferative diseases 
• Myelodysplastic/myeloproliferative diseases 
• Myelodysplastic syndromes 
• Acute myeloid leukemia’s 
The WHO classification system puts a few 
diseases that show characteristics of both 
myeloproliferative and Myelodysplastic 
conditions into a new, separate group 
(myeloproliferative/Myelodysplastic diseases). 
Chronic myeloproliferative 
diseases (MPD) 
• Chronic myelogenous leukemia 
(CML) 
 
• Agnogenic myeloid metaplasia with 
myelofibrosis (MF) 
• (Idiopathic myelofibrosis) 
• Polycythemia Vera (EV) 
• Essential thrombocytemia (ET) 
• CML Ph+: t(9;22)(qq34;q11), BCR/ABL 
• Chronic neutrophilic leukemia 
• Chronic eosinophilic 
leukemia/hypereosinophilic syndrome 
• Chronic idiopathic myelofibrosis 
• Polycythemia Vera 
• Essential thrombocytemia 
CML 
The most important change is that only the Ph+ 
cases are called CML by the WHO. The Ph- 
cases (which show Myelodysplastic signs, and 
are known to have significantly worse 
prognosis) are called a CML (atypical CML), 
and belong to the newly created 
Myelodysplastic/myeloproliferative group. The 
aCML term is somewhat misleading, because it 
is not CML at all, but it was kept, having no 
better alternative. 
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Myelodysplastic/ 
myeloproliferative diseases 
• CMML belonged to the MDS in the 
FAB classification. About one half of the 
cases show proliferative, the other dysplastic 
signs, but it looks like these are just different 
forms of the same disease. 
• Atypical myelogenous leukemia (aCML) 
• Chronic myelomonocytic leukemia (CMML) 
• Juvenile myelomonocytic leukemia (JMML) 
 
Acute myeloid leukemia’s 
(AML) 
• M0: minimally differentiated 
• M1: myeloblastic leukemia without 
maturation 
• M2: myeloblastic leukemia with 
maturation 
• M3: hypergranular promyelocytic 
leukemia 
• M4: myelomonocytic leukemia 
• M4Eo: variant, increase in marrow 
eosinophils 
• M5: monocytic leukemia 
• M6: erythroleukemia (DiGuglielmo's 
disease) 
• M7: megakaryoblastic leukemia 
• AML with recurrent cytogenetic 
translocations 
• AML with t(8;21)(q22;q22)
AML1/CBFalpha/ETO 
 
The changes are easily summarized: the 
leukemia’s with consistent cytogenetic 
abnormalities and those that are MDS related 
were taken into separate groups; the rest of the 
old FAB classification was put under the 
"AML not otherwise categorized" entry. 
• Acute promyelocytic leukemia:
AML with t(15;17)(q22;q12) and variants 
PML/RARalpha 
• AML with abnormal bone marrow eosinophils 
inv(16)(p13;q22) vary t(16;16)(p13;q22) 
CBFbeta/MYH1 
• AML with 11q23 MLL abnormalities 
• AML with multilineage dysplasia 
• With prior MDS 
• Without prior MDS 
• AML with Myelodysplastic syndrome, 
therapy related 
• Alkylating agent related 
• Epipodophyllotoxin related 
• Other types 
• AML not otherwise categorized 
• AML minimally differentiated 
• AML without maturation 
• AML with maturation 
• Acute myelomonocytic leukemia 
• Acute monocytic leukemia 
• Acute erythroid leukemia 
• Acute megakaryocytic leukemia 
• Acute basophilic leukemia 
• Acute panmyelosis with myelofibrosis 
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Philadelphia  (Ph)  chromosome  
 
 
 
 
 
 
 
 
 
 
Figure 1.8: 
A diagram showing the  Philadelphia  (Ph)  chromosome, chromosome 9  and 22  
and  the  translocation 9;22 (q34;q11) ( Gunter et al, 1998). 
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1.9 Chemotherapeutic drugs: 
 
1.9.1 Cytarabine: 
 
Figure 1.9: 
Cytarabine (cytosine arabinoside) is an antimetabolic agent which specifically is a 
pyrimidine antagonist. Its chemical name is 1β- arabinofuranosylcytosine. Its 
chemical formula is C9H13N3O5 and its molecular mass is 243.217 g/mol. In vivo, 
13% is protein bound and there is 20% bioavailability when taken orally. The half 
life is biphasic: the initial is 10 minutes and the secondary is 1-3 hours and longer 
with continuous intravenous infusion. It is metabolized in the liver and 70-80% is 
excreted in urine. The common side effect is cerebellar toxicity.  
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Cytarabine acts only when it’s rapidly converted into cytosine arabinoside which 
competitively inhibits DNA polymerase. This results in DNA damage and causes 
cell cycle retardation at S-phase during the synthesis of DNA. DNA incorporation 
leads to chain elongation and causes defective DNA fragmentation at S phase of 
rapidly dividing cells. Cytosine arabinoside inhibits both the DNA and RNA 
polymerases and nucleotide reductase enzymes needed for DNA synthesis. 
Cytarabine is metabolised by rapid conversion into the inactive uracil derivative 
(Nowrousian et al, 1985) (Figure 1.9).
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1.9.2 Etoposide:  
Figure 1.10:  
Etoposide is a chemotherapeutic drug used to treat certain types of human cancer. It 
is a topoisomerase 2 inhibitor and is derived from podophyllotoxin of plant origin. 
Its systematic name is 4-demethyl-epipodophyllotoxin 9-{4, 6-O-(R)-ethylidene-
beta-d-glucopyranoside} 4-di-hydrogen phosphate. Its chemical formula is 
C29H32O13 and it has molecular mass of 588.557g/mol.  
It has 25-75% bioavailability and 97% protein binding and a half-life of 6 hours 
when taken orally; this extends up to 12 hours if given intravenously. It is 
metabolized in the liver and excreted in urine and faeces. The common side effects 
are low blood pressure, hair loss, metallic taste and bone marrow suppression. 
Topoisomerases are essential enzymes which exist in all pro-and eukaryotic cells. 
They play a crucial role in the maintenance and replication of DNA during cell 
proliferation.  These ubiquitous enzymes remove any defect formed by transient 
double-strand breaks (Baldwin EL et al 2005). Topoisomerase 2 inhibition results in 
stabilization of DNA double strand breakage. Thus accumulation of cleavage 
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complexes in treated cells forms permanent DNA strand breaks which cause 
mutagenesis and chromosomal translocation. Etoposide acts via the known 
topoisomerase 2 enzymes which are multi subunit proteins which use ATP to adjust 
DNA topology by passing an unbroken helix through a transient double – stran 
break in DNA. After strand passage the DNA backbone is held and DNA structure 
restored. Etoposide changes topoisomerase 2 into a poison that introduces a high 
level of transient protein-associated breaks in the genome of treated cells (Kenneth 
et al 2006). Resistance to etoposide in multi-drug resistance (MDR) phenotype cells 
occurs in many different ways; mutations at ser-1106 in the topoisomerase 2 
molecule inhibits enzyme phosphorylation and reduces its response to 
etoposide(Baldwin et al, 2005)Figure 1.10 
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1.9.3 Nocodazole: 
This anti-neoplastic agent is an abenzimidazole derivative. Its chemical formula is 
C14H11N3O3S and it has a molecular weight of 301.32 kDa. It is used in 
chemotherapy because of its ability to rapidly depolymerise microtubules. 
Microtubules are linear protein polymers whose action is to regulate movement of 
vesicles, organelles such as Golgi apparatus, endoplasmic reticulum and most 
importantly, the movement of chromosomes during mitosis (Grigoriev et al, 1999). 
Microtubules are found in transition between one of two states: either elongation or 
rapid shortening. Nocadozole acts by depolymerising microtubules and preventing 
the formation of the metaphase spindle. This arrests mitosis, as the drug prevents the 
attachment of microtubules to the kinetochores. This detachment prolongs mitotic 
arrest and stimulates the spindle assembly checkpoint leading the cell to apoptosis. 
High doses of nocodazole prevent progression of cells into mitosis because of rapid 
depolymerization of microtubules. This causes mitotic apoptosis. A low 
concentration alters the microtubule dynamics arresting the cells at mitosis 
(Vasquez et al, 1997).  
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 1.9.4 Vinca alkaloids: 
 
 
 
Figure 1.11: 
 
 
 
 
 
 
 
 Vincristine is an alkaloid obtained from vinca rosea, a periwinkle plant. Its 
chemical formula is C46H56N4O10 and it has a molecular mass of 923.958g/mol. It 
has 75% protein binding and a half-life in vitro of 19-155 hours after intravenous 
infusion. It is metabolized in the liver where 90% is excreted in the bile and 10% 
excreted in the urine. The common side effect is peripheral neuropathy, 
hyponatremia, constipation and hair loss. This is one of several vinca alkaloids and 
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is a powerful anti-tumour drug. It targets tubulin, a member of a protein family 
where the most common members are α tubulin and β tubulin. Normally they bind 
to microtubules with tubulin GTP dimer and cause microtubule assembly. The 
mechanism of action of vincristine involves binding to tubulin and inhibiting the 
assembly of microtubules. In addition, vincristine causes depolymerization of 
microtubules. Spindle damage interferes with chromosomal segregation and leads to 
mitotic arrest at metaphase (Gigant et al, 2005). 
A low concentration of vincristine binds to microtubule tips and suppresses the 
dynamic instability of plus ends. A higher dose leads to microtubule 
depolymerization, causing proto-filament spirals and curls (Jordan et al, 1993). 
Vincristine (Figure 1.11) can be used as a tool to control the dynamic behaviour of 
microtubules in living cells (Gigant et al, 2005). 
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1.10   Aims: 
Many drugs used in cancer chemotherapy have been used for decades with varying 
degrees of success. Enhanced efficacy of these agents could come about by the 
design of new “small molecules” that would act as adjuvants to conventional 
regimens. Cells that are relatively resistant to chemotherapy provide a “time lapse” 
or “window of opportunity” to analyse the response of cells to chemical insult. 
As the BCR-ABL Philadelphia chromosome imparts a degree of drug resistance to 
cells, the aim of this study is to review and investigate the responses of K562, a 
BCR-ABL positive chronic myeloid leukaemia cell line, to etoposide and 
vincristine, drugs with differing modes of action 
I aim to: 
Determine the effect of each drug on proliferation 
Determine the effect of each drug on cell death. 
Determine the effect of drug concentration on these parameters 
Determine the effect of time on these parameters 
To investigate and discuss any common pathways that may lead to synergy for these 
agents 
To investigate and discuss potential targets for new alternative therapeutic targets 
that may enhance the effectiveness of these more traditional agents in managing 
leukaemia  
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Najood Omar   60
  
 
 
Chapter 2 
 
Materials and Methods 
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 2.1     Cell culture 
2.1.1  Cell lines & culture conditions: 
K562 cells were obtained from the European Collection of Animal Cell Cultures 
(ECACC) Proton Down, UK. These cells are derived from the K562 erythro-
myeloid leukemia cell line. They remain p53 negative in long term culture. The 
cells were propagated in RPMI 1640 medium containing 25mM N-(2-
hydroxyethyl)piperazine-N’-2-ethanesulphonic acid (HEPES), 10% v/v heat 
inactivated fetal bovine serum and 2mM L-glutamine. 
The cells were cultured in either 25 cm3 or 75 cm3 flasks and kept in a humidified 
incubator containing 5% CO2 at 37°C. Aseptic techniques and a laminar flow 
cabinet was employed to maintain the sterility of the cultures. Cells were grown in 
suspension at a density of 0.2-1.0×106 cells/ml for exponential cell growth and 
subculture every two-three days. 
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2.1.2    Cryopreservation and replenishment of leukemic cell line: 
Cells in exponential phase of growth (2-3 days of culture) were frozen in 
Cryopreservation medium .The cells were washed in RPMI 1640 medium, 
resuspended at a concentration of 1×107/ml in the above medium and aliquot was 
stored in 1 ml ampoules. These were placed in a 750 cm3 Nalgene™ cryo 1°C 
freezing container filled with 250 ml of isopropanol this achieves a cooling rate of -
1°C/min. The Nalgene™ cryo 1°C freezing container was placed at -70°C for 12 
hours. The ampoules of cells were then transferred to vats containing liquid nitrogen 
for long term storage. Cells were removed from liquid nitrogen every six months, 
washed three times in Hank’s balanced salt solution (HBSS) and resuspended in 
supplemented RPMI 1640 medium. At least three passages of the retrieved cells 
were allowed to occur before the fresh cells were used in any experiments. 
2.1.3    Cell viability testing: 
Cell viability was assessed by trypan blue dye exclusion. Since dead cells lose the 
integrity of their plasma membrane they are unable to exclude macromolecules such 
as trypan blue dye and viewed with a phase contrast microscope. 50 µl of 0.1% w/v 
trypan blue in HBSS and 50 µl of cells in suspension were mixed together and 
placed in a 96-microwell plate and incubated for 10 minutes at 37°C. All cells were 
counted using a haemocytometer. Dead cells showed blue staining of the cytoplasm 
and nucleus. Cell viability was calculated by: Percentage cell viability = 100 ×  total 
number of viable cells (unstained cells) total number of cells (stained and 
unstained). Optimal culture conditions were designated as greater than 95% cell 
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viability and experiments were only performed if the background level of cell death 
was less than 5%. 
 
2.1.4    Testing the effect of chemotherapeutic and chemical agents: 
K562 cells were incubated with, 0 µg/ml, 1 µg/ml and 20 µg/ml of cytarabine and 
etoposide for 4, 8, 24, 36 and 48 hours. A titration of vincristine dose was 
performed, a vincristine concentrations of 0.0, 0.1, 40 µg/ml were tested for at2, 4, 
6, 24, 48, 72 and 96 hours. For all experiments cells were seeded at a concentration 
of 0.25×106 cells/ml. Nocodazole was used at a concentration of 1 µg/ml all 
experiments. 
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2.2       Cell cycle analysis: 
2.2.1    Apoptosis and G2M arrest by flow cytometry:  
Exponentially growing K562 cells, were harvested, washed in medium and 
resuspended in supplemented RPMI 1640 medium at concentration of 0.25×106 
cells/ml. 2ml aliquots of this suspension were incubated in 24 well plates in the 
presence and absence of etoposide, nocodazole and vincristine. 
 Aliquots of 0.25×106 cells were removed washed twice in phosphate buffered 
saline (PBS)  and then fixed and permeabilised in 500 µl 70% ice-cold ethanol for 
30 minutes at 4°C. The cells were then washed three times in PBS, resuspended and 
incubated at 37°C for 60 minutes in 1 ml of PBS containing 200 µg/ml RNAse and 
50 µg/ml propidium iodide  The fluorescence of propidium iodide stained nuclei 
was measured on a flow cytometry using either a Coulter Epics XL4-MCL or a 
Becton Dickinson FacsVantage flow cytometer with pulse processing for aggregate 
discrimination, a band pass filter on PMT3 at a wavelength of 620nm and System II 
Lyses 3 software or Cell Quest software respectively.  
Analysis of 10,000 cells yielded a histogram of DNA content distribution. Apoptotic 
cells were defined as the sub G0 peak the lower content of DNA was therefore a 
feature used to detect apoptotic cells compared to the controls which are untreated 
cells. 
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2.2.2    Detection of apoptosis with annexin V immunostaining: 
K562 cells, were harvested, washed in medium and resuspended in supplemented 
RPMI 1640 medium at 0.25×106 cells/ml in 2ml volumes in 24 well plates in the 
presence and absence of etoposide, and vincristine . Aliquots of 0.5×106 cells were 
then removed and washed with cold (PBS) and then cells were  resuspended  
in100µl of 1x binding buffer in a test tube to which was added  5µl of 
fluoresceinated  annexin V antibodies.  
The cells were mixed gently and incubated in 400µl of binding buffer at 20c°for 
15mints in the dark and then analyzed by flowcytometry within 1 hour. In each 
experiment, controls were untreated cells from the same culture stained by similar 
protocols. 
2.3      Whole cell protein extraction: 
2×107 cells were washed twice in HBSS and centrifuged at 1,400 rpm for 5 minutes 
to pellet the cells. The cells were then homogenized in 1 ml 
radioimmunoprecipitation (RIPA) buffer Cells were sheared on ice by repeated 
passage through a 19 gauge microlance needle and a 1 ml syringe. The sample was 
left on ice for 60 minutes and the cells were sheared every 15 minutes for twenty 
strokes each time. Insoluble cellular debris was removed by centrifugation for 10 
minutes at 4,000 rpm. The supernatant was removed, transferred to Eppendorf tubes 
and stored at -70 °C. 
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2.3.1    Protein quantification using the direct Lowry method: 
The Lowry reaction works by peptide bonds forming a blue colour when complexes 
with an alkaline cupric tartrate reagent. Protein standards using different 
concentration of bovine serum albumin were prepared in a volume 1 ml of 10 µl of 
protein lysate samples were diluted with 990 µl of deionised water. 1 ml of Lowery 
reagent solution was added to the standard and sample tubes and left at room 
temperature for 20 minutes. With rapid and immediate mixing, 500 µl of Folin & 
Ciocalteu’s Phenol Reagent Working Solution was added to each tube and the color 
allowed developing for 30 minutes. The samples were then transferred in triplicate 
to a 96-microwell enzyme-linked immunosorbant assay (ELISA) plate and read at a 
wavelength of 750nm on an ELISA plate reader. The readings were completed 
within 30 minutes. The sample concentrations were calculated from the prepared 
protein standards by linear regression analysis. The protein concentration of the 
samples were determined using the equation Y = a + bX where Y is the optical 
density value and X is the protein concentration.  
 
2.4   Sodium dodecyl sulphate (SDS)-polyacrylamide gel electrophoresis 
(PAGE) protein preparation: 
Precisely 50 µg of cellular lysate as determined by the direct Lowery method were 
placed in 20 µl of RIPA buffer and 10 µl SDS-PAGE sample loading dye .The 
samples were heated to 100°C for 5 minutes in a dry block heater, allowed to cool 
and then centrifuged at 1,300 rpm for 1 minute in a minicentrifuge. 
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2.4.1    Relative molecular weight determined by SDS-PAGE electrophoresis: 
Pre stained standard protein molecular weight markers ranging from 14.3 kDa to 
220 kDa were prepared by mixing 10 µl of the pre stained Rainbow™ marker with 
10 µl of RIPA buffer and 10 µl of SDS-PAGE sample loading dye. The mixture of 
molecular weight markers was heated to 100°C for 5 minutes in a dry block heater, 
allowed to cool and then centrifuged at 1,300 rpm for 1 minute in a minicentrifuge. 
The pre stained standard protein molecular weight markers were run alongside the 
samples to determine the relative size of the protein of interest.  
2.5     Western Blotting: 
2.5.1    Preparation of SDS-PAGE mini gel 
The two glass plates of the Bio-Rad Mini Protein II™ western blotting 
electrophoresis tank were cleaned in detergent, washed in de-ionized water and 
wiped with 70% methanol and allowed to air dry. The plates were assembled in a 
clamp holder using 0.5mm spacers and transferred onto a casting platform. An SDS-
PAGE solution was prepared. Different percentage gels were prepared according to 
the molecular weight of the protein to be analyzed  3.5 ml of the gel solution was 
poured between the glass plates mounted in the assembled clamp holder, covered 
with 0.5 ml water and allowed to polymerise for approximately 1 hour. When the 
gel had set the water was washed off. The gel was then overlaid with a stack gel  A 
10 well comb was inserted into the stack gel solution which was also allowed to 
polymerize for 1 hour.  
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2.5.2     Protein electrophoresis:  
The comb was removed from the polymerised SDS-Polyacrylamide gel (PAG), 
which was transferred in the clamp holder to an electrode assembly where it was 
clipped into position to form the inner reservoir chamber. 500 ml of electrode buffer 
was prepared and used to fill the inner reservoir chamber. The apparatus was 
transferred to the gel tank containing the remaining electrode buffer. Air bubbles 
were allowed to disperse from the wells before the samples were loaded. The 
Rainbow™ coloured protein molecular weight marker was loaded in the first lane of 
each gel, followed by precisely 50 µg per lane of cellular protein lysate. 
Electrophoresis was performed at a constant voltage of 100V for 90 minutes.   
 
2.5.3    Electroblotting onto Immobilon-P polyvinylidene difluoride (PVDF) 
membranes: 
After the completion of electrophoresis, the gels were removed from the glass plates 
and the stack gel discarded. The SDS-PAGE along with two blotting pads and a 
sheet of PVDF membrane were presoaked in separate containers containing transfer 
buffer for 30 minutes. One of the presoaked blotting pads, on which the gel was 
positioned, was placed in a clamp holder, the PVDF membrane was then layered on 
top of the gel and air bubbles removed by rolling a pipette over the membrane. The 
final blotting pad was placed on top of the membrane and the clamp holder closed 
and clipped shut. The clamped assembly was then positioned in the immersion 
electro blotter transfer tank with the gel facing the cathode and the membrane facing 
the anode. The tank was then filled with transfer buffer. A cooling system was 
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inserted into the transfer tank and the gels were electro blotted at a constant voltage 
of 30V for 14 hours. After the transfer was complete the membranes were allowed 
to air dry for 5 minutes before being stored at 4°C between two dry blotting pads, 
covered in Saran wrap.®
 
2.5.4    Immune-staining of blots: 
Determination of expression of CDK1, Bax, cyclin a, cyclin B, survivin, Aurora B, 
cyclin B tyrosine 15 phosphorylation. Membranes were immunostained with an 
anti-β-actin antibody to ensure equal loading of the samples per lane. The PVDF 
membrane was rehydrated for one hour in Tris (hydroxymethyl amino methane 
buffered saline (TBS) (Appendix 9.1.13) containing either 0.05% v/v or 0.1% v/v 
Tween-20® (TBST) (Appendix 9.1.13) for monoclonal and polyclonal antibodies 
respectively. Whilst the membrane was hydrating it was cut into strips to separate 
the lanes containing protein which were visible during the rehydration process. The 
hydrated membrane strips were positioned inside 50 ml Falcon tubes, placed on a 
rolling mixer platform and non specific protein binding was blocked at 4°C by 
incubation in 5% w/v dried milk powder in TBST solution for one hours. The 
membrane was then briefly washed in TBST for 5 minutes before being incubated 
in a 50 ml Falcon tube containing a solution of primary antibody (at predetermined 
optimized concentrations, Appendix 9.1.13) and 1% w/v dried milk powder in TBS 
for 1 hour at 4°C on a rolling mixer platform. The membrane was then washed six 
times, for 10 minutes each in TBST before being incubated in a 50 ml Falcon tube 
Najood Omar   71
containing the horse radish peroxidase (HRP) conjugated secondary antibody (either 
goat anti-mouse antibody or goat anti-rabbit antibody as appropriate (Appendix 
9.1.13) in 1% w/v dried milk powder in TBS for 1 hour at 4°C on a rolling platform 
mixer. Excess secondary antibody was removed by a further four washes of 10 
minutes each in TBST followed by two washes for 10 minutes in TBS.  
2.5.5    Anti-phospho-tyrosine antibody immunostaining: 
The PVDF membranes were re-hydrated in 0.1% v/v TBST for one hour. Whilst the 
membrane was hydrating it was cut into strips to separate the visible lanes 
containing the protein. The hydrated membrane strips were placed in a 50 ml Falcon 
tube on a rolling mixer platform. Non specific protein binding was blocked in 5% 
w/v BSA in TBST (Appendix 9.1.14) at 4°C for one hour. The membrane was 
briefly washed in TBST before being incubated in a 50 ml falcon tube, containing 
the HRP conjugated anti-phospho-tyrosine antibody (Appendix 9.1.14) in TBST, at 
4°C for one hour on a rolling platform mixer. Excess antibody was removed by four 
a further for 10 minutes washes TBST followed by two washes for each in TBS.  
2.5.6    Visualization of protein bands using enhanced chemiluminescences: 
Enhanced chemiluminescence’s (ECL) (Appendix 9.1.15), utilizes the highest 
emitted reaction when hydrogen peroxidase catalyses the oxidation of luminal in 
alkaline conditions.  Following oxidation. Luminal is in an excited state which then 
decays to ground state via a light emitting pathway. Since Tween-20® greatly 
diminishes the light output, Tween-20® was omitted from the wash solution for the 
last two washes. Membranes were incubated with ECL for 2 minutes before the 
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excess was blotted away. The membranes were then placed in a Rexel plastic wallet 
holder and exposed to blue light sensitive autoradiography film, ‘Hyperfilm’ 
(Appendix 9.1.15). The Hyperfilm was exposed to the membrane for between 5 
seconds and 1 hour depending upon the strength of the bands achieved after post 
development. The Hyperfilm was developed in Xograph Imaging Systems Compact 
×4 automatic developing machine. 
2.5.7    Immunopreciepitation of survivin and Cdk1 by western blotting: 
The phosphorylation status of the tyrosine residue 15 in CDK1 is indicative of its 
function. To assess differences in CDK1 phosphorylation status between cultures, 
CDK1 was immunoprecipetated using an anti-CDK1 antibody.  
 250 µl of appropriate anti-class specific coated Dynabeads (Appendix 9.1.16) were 
added to an Eppendorf tube and placed on a magnetic particle concentrator for 2 
minutes. The supernatant (preservation buffer containing sodium azide) was 
carefully removed so as not to disturb the collected beads. The Eppendorf tube 
containing the beads was then removed from the magnetic particle concentrator and 
1.5 ml of 0.1% w/v BSA in PBS (PBS/BSA) was mixed with the beads. The 
Eppendorf tube containing the beads was then placed on the magnetic particle 
concentrator for 2 minutes. Once again the supernatant was removed and the 
process of washing the beads in PBS/BSA to remove any traces of sodium azide 
(which inhibits antibody binding) was repeated three times. These washed beads 
were then incubated with 15 µg of primary antibody in 1.5 ml of PBS/BSA for 30 
minutes at room temperature and placed on a rolling mixer platform. After five 
washes in PBS/BSA to remove the excess primary antibody, 75 µl of  coated beads 
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were resuspended in 250 µl of PBS/BSA and added to 500 µg of cell lysate which 
was made up to a final volume of 1.5 ml with PBS/BSA. This was incubated at 4⁰C 
for 1 hour on a rolling mixer platform. The magnetically selected beads containing 
target Protein complexes were once again washed five times in PBS/BSA to remove 
any cell lysate containing non-bound protein.  
The washed beads with bound target-protein complexes were then eluted directly 
into 20 µl of SDS-PAGE loading dye. The samples were then heated to 100°C for 5 
minutes in a dry block heater to denature the protein and to destroy the antibody-
bead, antibody-antibody, and antibody-protein bonds. The samples were left to cool 
then centrifuged at 1,300 rpm for 1 minute in a micro centrifuge. The beads were 
separated from the sample by using the magnetic particle concentrator and the 
collected proteins were loaded onto an SDS-PAGE gel as previously described 
(2.4.2). The gel was then transferred onto PVDF membranes by Western blotting 
(2.4.3) and the membranes were then stained with an anti-phospho-tyrosine 
antibody (2.4.5). Survivin Immunopreciepitation was done with same technique. 
 
. 
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Result chapter 3 
 
 
Effects of cytarabine and etoposide on the cell cycle of K562 and 
HL60 cells 
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3.1       Introduction: 
Cytarabine is an anti metabolic agent which damages DNA. It is rapidly converted 
to the active form cytosine arabinoside, which by competing with pyrimidine, 
inhibits DNA and RNA polymerase and nucleotide reductase enzymes. This 
inhibition of DNA synthesis arrests the cell cycle during DNA replication (S-phase).  
Etoposide, on the other hand, inhibits topoisomerase 2, one of the important DNA 
repair enzymes. Inhibition of topoisomerase 2 causes persistence of DNA strand 
breakages. In the absence of repair by topoisomerase 2, these DNA breakages lead 
to permanent mutations and even chromosomal translocations. Persistence of DNA 
strand breaks caused by topoisomerase 2 inhibition also induces other repair or 
apoptosis mechanisms mediated by p53 gene (Baldwin et al, 2005).  
The following experiments show the effects of these two drugs, cytarabine and 
etoposide on K562 cells and HL60 cells both of which are p53 deficient. The use of 
apoptosis resistant K562 cells allows the accumulation of DNA damaged cells 
which facilitates the study of the mechanism of cell death and resistance to 
genotoxic drugs.   
Flow cytometry measurement of DNA and immunostaining using an anti-phospho 
histone H3 ser10 antibody were used to detect cells in mitosis.  
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3.2         Aims: 
 -To study the effect of the DNA damaging agents cytarabine and etoposide on 
the induction of apoptosis and cell cycle distribution of K562 and HL60 myeloid 
leukemia cells line. 
 -To determine whether these effects are time and concentration dependent. 
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3.3 Results: 
3.3.1      Effect of   cytarabine on K562 cells: 
 K562 cells were incubated with different concentrations of cytarabine   (0-
80µg/ml).  The harvested cells were stained with propidium iodide. The degree of 
apoptosis and cell cycle distribution was determine via flow cytometry.  
Induction of apoptosis in K562 cells with 80µg/ml cytarabine was measured as 7.7% 
+/_1.9, 9.3% +/_2.3, 17.0% +/_4.2, 15.3% +/_3.3, 17.1% +/_4.2 of the total 
population at 4, 8, 24, 36 and 48hrs respectively. This shows an induction of 
apoptosis significantly greater than control cultures at time points of 24hrs and 
longer. Other concentrations of cytarabine did not induce appreciable amounts of 
apoptosis when compared to control cultures although small standard errors in 
measurement resulted in statistical significance in some instances. Thus, the 
percentage apoptosis induced by 20µg/ml was 7.2% +/_1.9, 10.3%+/_3.1, 11.2% 
+/_3.0, 10.2% +/_2.1, 10.0% +/_2.1 at 4, 8, 24, 36 and 48hrs respectively; a dose of 
5µg/ml induced apoptosis of 7.7% +/_1.9, 10.3% +/_2.3, 11.2% +/-3.0, 10.2% +/_2.1, 
10.0% +/_2.1 at 4, 8, 24, 36 and 48hrs respectively and a dose of 1µg/ml cause 
apoptosis of about 8.3% +/_1.6, 10.9% +/_2.0, 7.4% +/_1.5, 10.1% +/_0.6, 8.4% 
+/_0.9 at 4, 8, 24, 36 and 48hrs respectively (figure 3.1). 
The percentage of cells accumulating in G2M after incubation with cytarabine was 
also measured. As with the induction of apoptosis, significant changes in G2M were 
observed only in cells cultured with drug at 80µg/ml for 24hrs or longer when 
compared to control. G2M arrest in K562 cells induced with 80µg/ml was 6.0% +/-1.2, 
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6.3% +/_1.3, 6.4% +/_0.7, 6.5% +/_1.1, 6.7% +/_1.0 at 4, 8, 24, 36 and 48hrs 
respectively. The timepoints of 24hr or longer showed a reduction in G2M arrest when 
compared to controls. Other concentrations of cytarabine did not significantly alter 
G2M accumulation although some G2M arrest was seen at 24hrs with lower 
concentrations of cytarabine. Thus, a dose of 20µg/ml caused a percentage G2M arrest 
of 6.8% +/_1.7, 6.3% +/_1.2, 12.4% +/_1.3, 12.5% +/_0.9, 11.6% +/_1.5 at 4, 8, 24, 36 
and 48hrs respectively; a dose of 5µg/ml induce G2M arrest of 7.9% +/_1.7, 6.5% 
+/_0.9, 19.6%+/_2.6, 12.8% +/_1.6, 11.7% +/_2.4 at 4, 8, 24, 36 and 48hrs 
respectively and a dose of 1µg/ml induced G2M arrest of 7.57% +/_1.7, 6.3% +/_0.7, 
17.7% +/_1.5, 11.8% +/_1.8, 11% +/_2.3 at 4, 8, 24, 36 and 48hrs respectively (figure 
3.4). 
There was also a concomitant change in the percentage of cells accumulating in the 
G1 and S-phases of the cell cycle. The percentage of K562 cells in the G1 phase 
after incubation with 80µg/ml cytarabine was 55.3% +/_ 1.6, 55% +/_1.8, 46.5% 
+/_2.5, 43.9% +/_2.9, 41.6% +/_4.1 at 4, 8, 24, 36 and 48hrs respectively. Dose of 
20µg/ml induced G1 phase percentages of 54.5% +/_1.1, 52% +/_2.1, 31.8% +/_1.6, 
30.9% +/_5.6, 34.2% +/_5.7 at 4, 8, 24, 36 and 48hrs respectively. Dose of 5µg/ml 
induce G1 cells at 52.2% +/_1.1, 50.4% +/_1.8, 35.2% +/_4.6, 43.4% +/_2.4, 46.4% 
+/_4.3 at 4, 8, 24, 36 and 48hrs respectively. Dose of 1µg/ml induce G1 cells at 50.6% 
+/_0.4, 48.3% +/_1.4, 44.4% +/_2, 48.8% +/_1.3, 50.9% +/_ 2.5 at 4, 8, 24, 36 and 
48hrs respectively (figure 3.2). 
The percentage accumulation of K562 cells in S phase after incubation with 80µg/ml 
cytarabine was 28.7% +/_2.5, 29.3% +/_ 3.4, 26.4% +/_3.1, 29.7% +/_1.8, 29.5% 
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+/_1.7 at 4, 8, 24, 36 and 48hrs respectively. Dose of 20µg/ml induce G1 cells at 
29.6% +/_2.2, 30.0% +/_1.9, 40.5% +/_3.5, 42.5% +/_5.6, 40.2% +/_5.7 at 4, 8, 24, 36 
and 48hrs respectively. Dose of 5µg/ml induce G1 cells at 30.2% +/_2.7, 32.0% 
+/_1.7, 32.2% +/_3.6, 31.0% +/_4.4,  29.6% +/_4.7 at 4, 8, 24, 36 and 48hrs 
respectively. Dose of 1µg/ml induce G1 cells at 31.1% +/_2.1, 32.7% +/_1.8, 26.25 
+/_1.4, 27.5% +/_2.6, 27.5% +/_2.6 at 4, 8, 24, 36 and 48hrs respectively (figure 3.3).  
This data shows that cytarabine has little effect on the induction of apoptosis over an 
8hr period. However, after 24hrs the highest concentration induced a significant 
increase in apoptosis but there was no subsequent increase over a further 24 hr 
period. Lower concentrations did not induce apoptosis suggesting this effect is not 
concentration dependent. The induction of apoptosis by 80µg/ml cytarabine was 
mirrored by a significant fall in the percentage of cells detected in G2M.   
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 3.3.2   Effect of etoposide on K562 cells: 
 K562 cells were incubated with different concentrations of etoposide (0-80µg/ml). 
The harvested cells were stained with propidium iodide and cell DNA content was 
measured by flow cytometry to study apoptosis and the distribution of cell in the 
stages of cell cycle.   
The percentage apoptosis induced in K562 cells with 80µg/ml was 13.1% +/_3.7, 
14.4% +/_3.2, 29.8% +/_7.9, 27.0% +/_5.3, 41.8% +/_3.3 at 4, 8, 24, 36 and 48hrs 
respectively. The percentage of apoptotic cells induced by  20µg/ml was 10.4% 
+/_3.0, 10.4% +/_2.6, 19.1% +/_4.8 and 31.0% +/_5.8 at 4, 8, 24, 36 and 48hrs 
respectively. The percentage apoptosis induced by 5µg/ml was 9.7% +/_2.3, 9.3% 
+/_2.6, 10.5% +/_2.8 and 16.3% +/_3.8 at 4, 8, 24, 36 and 48hrs respectively 
and1µg/ml induce apoptosis of 9.2% +/_2.1, 9.7% +/_2.8, 7.8% +/_2.3, 13.1% 
+/_1.9 at 4, 8, 24, 36 and 48hrs respectively. These data show in contrast to 
cytarabine a time and concentration dependent induction of apoptosis (figure3.5). 
The percentage of cells accumulating in G2M after incubation with etoposide was 
also measured. The percentage G2M arrest of K562 cells induced with 80µg/ml 
etoposide was 7.8% +/_2.6, 6.9% +/_1.7, 5.5% +/_0.4, 6.9% +/_ 1.4, 5.3% +/_1.1 at 4, 
8, 24, 36 and 48hrs respectively. Dose of 20µg/ml induce G2M arrest at 7.8% +/_1.2, 
10.0% +/_2.3, 12.2% +/_1.8, 13.0% +/_2.2, 13.8% +/_4.0 at 4, 8, 24, 36 and 48hrs 
respectively. Dose of 5µg/ml induce G2M arrest at 8.0% +/_0.9, 9.7% +/_2.1, 22.2% 
+/_3.9, 20.4% +/_4.3, 29.1% +/_7.8 at 4, 8, 24, 36 and 48hrs respectively and a dose of 
1µg/ml induce G2M arrest at 8.9% +/_1.8, 10.6% +/_2.6, 26.3% +/_3.8, 21.9% +/_4.8, 
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23.9% +/_5.9 at 4, 8, 24, 36 and 48hrs respectively. Again, a concentration-dependent 
effect is seen when measuring this parameter. Low concentrations of etoposide 
induced cell cycle arrest at G2M whereas higher concentrations abolished cell cycle 
arrest and therefore the G2 and mitotic cell cycle checkpoints (figure 3.8). 
There was also a change in cell accumulation in G1 and S-phase. The percentage K562 
cells accumulated at G1 phase at a dose of 80µg/ml was 43.7% +/_1.2, 45.1% +/_1.0, 
34.6% +/_4.0, 39% +/_1.6, 27.5% +/_1.3 at 4, 8, 24, 36 and 48hrs respectively. Dose 
of 20µg/ml induce cell accumulation at G1 phase of 45.4% +/_0.9, 43.6% +/_0.7, 
25.7% +/_3.3, 26.6% +/_2.6, 19% +/_3.1 at 4, 8, 24, 36 and 48hrs respectively. Dose 
of 5µg/ml induced cells in G1 phase arrest of 43.2% +/_1.6, 43.4% +/_0.9, 40.6% 
+/_5.7, 40.5% +/_4.4, 29.6% +/_7.8 at 4, 8, 24, 36 and 48hrs respectively and a dose of 
1µg/ml induced G1 phase arrest of 43.4% +/_2.1, 44.9% +/_1.8, 33.8% +/_4.2, 36.1% 
+/_5.8, 35.1% +/_5.9 at 4, 8, 24, 36 and 48hrs respectively (figure 3.6). 
The percentage accumulation of K562 cells in S-phase after incubation with 80µg/ml 
was 33.3% +/_2.7, 33% +/_3.2, 25.1% +/_2.8, 25.5% +/_3, 27.5% +/_1.3 at 4, 8, 24, 
36 and 48hrs respectively. A dose of 20µg/ml induced S phase arrest of 34.1% +/_2.8, 
35.9% +/_2.5, 38.9% +/_5.2, 39.9% +/_4.7, 34% +/_5.1 at 4, 8, 24, 36 and 48hrs 
respectively. A dose of 5µg/ml induced  S phase arrest of 37.6% +/_3.3, 36.1% +/_3.1, 
40.6% +/_5.7, 40.5% +/_4.4, 29.6% +/_2.6 at 4, 8, 24, 36 and 48hrs respectively and a 
dose of 1µg/ml induce accumulation of cells at S phase of 35.2% +/_2.7, 27.5% 
+/_7.5, 29% +/_2.2, 29.7% +/_2.7, 24.9% +/_1.6 at 4, 8, 24, 36 and 48hrs respectively 
(figure 3.7). 
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This data show that the effects of etoposide, in contrast to the effects of cytarabine, are 
both time and concentration dependent. However, the inverse relationship between the 
induction of apoptosis and G2M cell cycle arrest was true for etoposide as well as 
cytarabine. 
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3.3.3       Effect of etoposide on HL60 cells: 
A similar series of experiments with etoposide were performed on the HL-60 cell line. 
A similar effect was observed to that seen in K562 cells although time courses and 
drug concentrations were shorter and smaller respectively, indicative of a cell line far 
more sensitive to the effects of etoposide. The relationship between G2M arrest and 
lack of apoptosis was again demonstrated in this cell line. HL60 cells were incubated 
with etoposide at concentrations of 0 and 0.1µg/ml. After 24 hours the harvested cells 
were stained with propidium iodide and the DNA concentrations analyzed by flow 
cytometry to assess their distribution to the phases of cell cycle. Treated HL60 cells 
showed high levels of G2M arrest of >60% compared to 25% in control cells (p<0.05) 
Significant G2M arrest was seen at 24hours (Figure 3.10). 
DNA content analysis cannot distinguish between G2 and mitosis as the DNA content 
is the same. Therefore cells were stained for a mitotic marker and analysed by flow 
cytometry. HL-60 cells were incubated with etoposide to induce G2M cell cycle 
arrest. Nocodazole was used as a positive control to induce mitotic cell cycle arrest. 
Very few cells incubated with etoposide were positive for the mitotic marker, 
phosphorylated histone H3 ser10 (figure 3.11). More specifically, when the cells in 
G2M were gated, less than 5% of etoposide treated cells were positive for the mitotic 
marker, compared to 35% of control cells (p<0.05).  These findings confirm that 
etoposide causes G2 phase arrest and these cells do not enter mitosis. 
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Effect of cytarabine on the rate of apoptosis in K562 cells 
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Figure 3.1: 
 
Flow cytometric analysis of K562 cells showing the percentage of apoptotic cells. All 
test cultures were compared to control cultures by unpaired student t-test (*P<0.05). 
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Effect of cytarabine on G1-phase in K562 cells 
 
 
 
Figure 3.2: 
 
Flow cytometric analysis of K562 cells showing the percentage of cells at G1 phase. 
All test cultures were compared to control cultures by unpaired student t-test 
(*P<0.05). 
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 Effect of cytarabine on S - phase in K562 cells. 
 
 
 
Figure 3.3: 
 
Flow cytometric analysis of K562 cells showing the percentage of cells at S- phase. All 
test cultures were compared to control cultures by unpaired student t-test (*P<0.05). 
 
 
 
 
         
Najood Omar   88
 Effect of cytarabine on G2M phase in K562 cells. 
 
 
 
 
 
Figure 3.4: 
 
Flow cytometric analysis of K562 cells showing the percentage of cells in G2M phase. 
All test cultures were compared to control cultures by unpaired student t-test 
(*P<0.05). 
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 Effect of etoposide on apoptosis in K562 cells. 
 
Figure 3.5: 
 
Flow cytometric analysis of K562 cells showing the percentage of cells at 
G2Mphase. All test cultures were compared to control cultures by unpaired student t-
test (*P<0.05). 
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Effect of etoposide on G1-phase in K562 cells. 
 
 
      
 
 
   Figure 3.6: 
 
Flow cytometric analysis of K562 cells show the percentage of cells at G1 phase. 
All test cultures were compared to control cultures by unpaired student t-test 
(*P<0.05). 
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Effect of etoposide on S-phase in K562 cells. 
 
 
 
 
Figure 3.7: 
Flow cytometry analysis of K562 cells showing the percentage of cells at S-phase. 
All test cultures were compared to control cultures by unpaired student t-test 
(*P<0.05). 
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Effect of etoposide on G2M phase in K562 cells. 
 
 
 
 
 
Figure 3.8:  
 
Flow cytometric analysis of K562 cells showing the percentage of cells at G2M-
phase. All test cultures were compared to control cultures by unpaired student t-test 
(*P<0.05). 
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Effect of etoposide on G2M phase of HL60 
cell line. 
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Figure 3.9: 
Flow cytometric analysis of HL60 cell line showing the percentage of cells at G2M 
phase treated with 0.1µg/ml etoposide after 24hrs. All test cultures were compared to 
control cultures by student t-test (*P<0.05). 
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Detection of histone H3 serine 10 phosphorylation as a marker of mitosis  
 
                     Control                      Nocodazole                   Etoposide 
 
 
 
 
 
 
 
 
 
Figure 3.10: 
 Representative flow cytometry histograms of low-percentage staining of cells in 
etoposide-induced cell cycle arrest indicative of G2 phase. Nocodazole was used as 
a positive control to induce mitotic cell cycle arrest. (From Davies D and Allen P 
(Supervisor). DNA Analysis by Flow Cytometry pp165-179. In Flow Cytometry, 
Principles and Applications. Ed Marion G Macey. Humana Press 2007).  
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Effect of etoposide on the immunostaining of HL60 cells stained with H3Ser10 
fluorescent antibody. 
 
 
 
 
 
 
 
 
 
 
Figure 3.11: 
 
Flow cytometric analysis of HL60 cells showing the percentage of cells at G2M 
phase after treatment with 0.1µg/ml for 24hrs of etoposide, and then stained with 
anti phospho-H3Ser10 antibody, a mitosis specific marker. All test cultures were 
compared to control cultures by unpaired student t-test (P<0.05). 
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3.4        Discussion: 
My experiments show the effect of etoposide and cytarabine on a K562 CML cell 
line which is resistant to apoptosis. The effect of etoposide and cytarabine was 
analysed by flow cytometry. This technique showed that etoposide treatment 
induced G2 arrest; however the highest doses also caused apoptosis. These findings 
confirm experiments by other workers in different models (Martins et al, 1997). 
More than one mechanism may be involved: the first having a lower threshold and 
causing G2M arrest while the second could have a higher threshold that causes 
apoptosis. 
In contrast, the effects of cytarabine were not dose related. This may be because 
cytarabine requires an enzyme to generate the active form and this is a rate limiting 
step. So even though the dose of cytarabine was increased there was no additional 
increased effect on the cells, presumably because the rate of conversion to the active 
form remains steady. 
This contrasts with etoposide which acts directly and does not require enzyme 
conversion to an active form. The higher the dose of etoposide, the more apoptosis 
is induced. Low doses cause cell cycle arrest; high doses cause apoptosis. Both of 
these observations have important implications for the treatment of leukaemia 
patients by chemotherapy. 
In eukaryotic cells the chromatin contains four core histone proteins known as H2A, 
H2B, H3 and H4. Phosphorylation of Ser10 of histone H3 is associated with 
chromosomal condensation during mitosis (Hendzel et al, 1997). Phosphorylation of 
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Ser 10 on H3 is therefore an indicator for mitosis. In this experiment 
immunostaining cells with anti-phospho H3 ser10 antibody confirms that the 
percentage of cells in mitosis was very low, suggesting that the arrested cells are 
restricted to the G2 phase of the cell cycle. Therefore, HL60 cells treated with 
etoposide showed high G2M arrest by 24hours compared to controls which was 
subsequently identified as  significant G2 arrest. Similar results were seen with 
etoposide in K562 cells (data not shown). 
Mechanistically, this is due to DNA strands breaks not being reunpaired during 
topoisomerase 2 inhibition. DNA damage therefore stimulates Chk1 which 
phosphorylates Ser-216 of Cdc25C and results in deactivation of cyclin B/Cdk1 as a 
key part of the G2M checkpoint (Williams et al, 2001).  
Escape of cells from mitosis may allow the cells to enter G1 phase at the border of 
the G1 checkpoint. This accumulation of abnormal cells in G1 phase may induce 
apoptosis. This can be caused by p21 activation and mediated by Bax proapoptotic 
protein. Activation of apoptosis in this model prevents damaged cells from re-
entering the cell cycle. This situation would fit in with the cellular adaptation 
theory. My data show that cells that die are not blocked at either G2 or M. This 
could be seen as a collapse of both the G2 and mitotic checkpoints i.e. cell cycle 
arrest and apoptosis are mutually exclusive. Thus another possibility is that entry 
into mitosis is the trigger for mitotic apoptosis. That is to say cells die immediately 
on entering mitosis and therefore cannot accumulate. An alternative form of cell 
death such as mitotic catastrophe may also take place . 
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3.5          Conclusions: 
 
-      G2 cell cycle arrest and apoptosis do not occur together in either K562 or HL60        
cells. 
      -     When there is G2 cell cycle arrest, apoptosis does not occur. 
       -    When apoptosis occurs there is diminished cell cycle arrest. 
       -    Cell death induced by etoposide post G2 arrest is due mainly to apoptosis. 
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 Results chapter 4 
 
 
 
 
Effect of vincristine on the cell cycle of K562 cells. 
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4.1       Introduction: 
K562 cells are a p53 negative cell line. They are resistant to cytotoxic drugs because 
their lack of p53 gene expression prevents p53-mediated apoptosis and leads to 
G2M cell arrest. Vincristine damages the mitotic spindle by depolymerising its 
microtubules. This arrests the cell at mitosis as a result of spindle assembly 
checkpoint activation. Under normal circumstances, the spindle assembly 
checkpoint is activated as a result of chromosome delay in attachment to the spindle. 
It recruits its active components Mad1, Mad2, Bub1, and BubR1 which then attach 
to kinetochores, accompanied by the chromosomal passenger protein survivin and 
Aurora B kinase.  
Activation of the spindle assembly checkpoint followed by mitotic slippage initiates 
apoptosis, by activating Bax which is a member of the Bcl-2 family of proteins. The 
Bcl-2 proteins alter mitochondrial membrane potential and this leads to release of 
cytochrome C and AIF. These proteins form a complex with procaspase 9, and by 
activation of caspase 9 they initiate apoptosis.  
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4.2       Aims: 
-To study the effect of various concentrations of vincristine on K562 cells. 
-To determine any relationship between cell cycle arrest and apoptosis 
-To determine evidence of mitotic slippage being a requirement for              
vincristine induced cell death. 
           . 
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4.3      Results: 
4.3.1    Effect of vincristine on K562 cells: 
Cells cultured with vincristine were stained with propidium iodide and analysed by 
flow cytometry to detect apoptosis and establish the distribution of cells in the 
various phases of the cell cycle. 
Apoptosis in K562 cells after incubation with a dose of 40µg/ml of vincristine was 
observed at 3.8% +/-0.6, 6.4% +/-1.2, 8.9% +/-0.7, 12.9% +/-1.3 and 23% +/-4.2 at 
4,24, 48, 72 and 96hrs respectively;  20µg/ml of vincristine increased apoptosis to 
4.5% +/- 1.1, 6.0% +/-1.0, 8.2% +/-0.4, 10.3% +/-1.4 and 15.3% +/-2.3 at 4, 24, 48, 
72 and 96hrs respectively;  10µg/ml of vincristine increased apoptosis to 3% +/-0.3, 
5.1% +/-0.1, 6.6% +/-0.8, 8.4% +/- 1.0, 9.5% +/-0.5 at 4, 24, 48, 72 and 96 hrs 
respectively;  5µg/ml of vincristine increased apoptosis to 3.3% +/-0.3, 5.2% +/-0.3, 
6.1% +/-0.3, 9.3% +/-0.5, 10.2% +/-1.0 at 4, 24, 48, 72 and 96hrs respectively when 
compared to control values of 2.6% +/- 0.3, 2.2% +/- 0.4, 1.6% +/- 0.1, 2.2% +/- 
0.7, 2.7% +/- 0.7 at the same time point (figure 4.1).  
 The percentage of K562 cells at G2M arrest increased significantly after incubation 
with 40µg/ml of vincristine to  39.1% +/-1.9, at 72 hrs ;  20µg/ml of vincristine  
increased G2M arrest to  49.5% +/-2.6, at 72hrs;  10µg/ml of vincristine induced 
G2M arrest of , 52.5% +/-6.0, 55.8% +/-4.2, 51.7% +/-1.3, 44.8% +/-4.7 at 24, 48, 
72 and 96hrs respectively;  5µg/ml of vincristine  increased G2M arrest to 57.3% +/-
5.9, 57.2% +/-5.4, 51.6% +/-0.9, 41.4% +/-3.6 at 24, 48, 72 and 96hrs respectively 
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when compared to control values of  26.5%+/- 1.9, 32.9%+/- 0.8, 27.2% +/- 1.1, 
30.3% +/- 1.2, 25.8% +/- 2.8 at same time points (figure 4.2). 
There were also compensatory changes in G1 and S-phases of the cell cycle. G1 
phase percentage of K562 cells when incubated with 40µg/ml of vincristine was 
significantly decreased to  30.6% +/-2.4, 32.6% +/-3.0 at 72 and 96hrs respectively;  
20µg/ml of vincristine caused a G1 phase percentage decreased to  31.6% +/-3.8, 
24.6% +/-1.9, 32.3% +/-4.2 at  24, 48, 72 and 96hrs respectively; 10µg/ml of 
vincristine reduce G1 phase percentage to 38.7% +/-4.5, 20.2% +/-2.4, 20.4% +/-
1.6, 23.6% +/-2.0 at  24, 48, 72 and 96hrs respectively;  5µg/ml of vincristine 
reduced G1 phase percentage to  22.8% +/-3.9, 20.7% +/-4.0  at  24, 48hrs 
respectively when compared to control values of 42.5% +/-1.7, 44.3% +/-0.5, 47.8% 
+/- 1.1, 45.3% +/-0.6, 49.9% +/- 2.2 at the same time points (figure 4.3). 
The S phase rate of K562 cells treated with 40µg/ml of vincristine was significantly 
reduced  to  20.2% +/-0.6 at 48hrs ; 20µg/ml of vincristine reduced S phase 
percentage to 18.4% +/-1.5 at 48hrs ; 10µg/ml of vincristine reduce S phase 
percentage to 4.3% +/-1.9, 17.3% +/-2.2,  at  24 and 48hrs respectively;  5µg/ml of 
vincristine increased  S phase percentage of 28.6% +/-2.3 at 4hrs and then reduced 
to 17.1% +/-2.4, 19.2% +/-1.5, 26.2% +/-3.8 at  48, 72 and 96hrs respectively. 
When compared to control values of 26.5% +/- 2.4, 20.4% +/-0.9, 23.7% +/-1.2, 
22.5% +/-1.3, 21.3% +/-2.4 respectively at the same time points (figure 4.4). 
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Effect of vincristine on apoptosis in K562 cells 
 
            Figure 4.1: 
Flow cytometric analysis of K562 cells showing the percentage of apoptotic cells. 
All test cultures were compared to control cultures by unpaired students t-test 
(*P<0.005). 
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Effect of vincristine on G2M in K562 cells 
 
 
 
Figure 4.2: 
 
Flow cytometric analysis of K562 cell line showing the percentage of G2M cells. 
All test cultures were compared to control cultures by unpaired students t-test 
(*P<0.005). 
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Effect of vincristine on G1 phase in K562 cells  
 
 
 
Figure 4.3: 
 
Flow cytometry analysis of K562 cell line showing the cells at G1 phase. All test 
cultures were compared to control cultures by unpaired students t-test (*P<0.05). 
 
 
 
 
 
Najood Omar   107
Effect of vincristine on S phase in K562 cells 
 
 
 
Figure 4.4: 
 
Flow cytometry analysis of K562 cell line showing the cells at S-phase. All test 
cultures were compared to control cultures by unpaired students t-test (*P<0.05). 
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               4.3.1   Effect of low doses vincristine on K562 cells: 
 
It was noted from figure 4.1 that the apoptosis induced by vincristine did not change 
with increasing drug concentrations in the lower range. There was very little 
difference in the apoptosis induced by 5, 10 or 20µg/ml up to 72hrs.  
Therefore a closer investigation of lower dose vincristine was carried out. Figure 4.5 
shows that over the course of the experiments the induction of apoptosis was 
actually inversely related to the concentration of vincristine at drug concentration 
below 20µg/ml. This was particularly evident at 48 and 72hrs where 0.02µg/ml was 
a more potent inducer of apoptosis than either of 0.10, 0.50, 2.50, 5.00 or 10µg/ml. 
Indeed at 72hrs, 0.02µg/ml was a better inducer of apoptosis than a 500 fold 
increase in drug concentration of 10µg/ml.  
Figure 4.6 shows that over the course of the experiments the induction of G2M 
arrest also decreased as the drug concentration of vincristine was increased up to 
20µg/ml. This was particularly evident at 24 and 72hrs where 0.02µg/ml was a more 
potent inducer of G2M arrest than either of 0.10, 0.50, 2.50, 5.00 or 10µg/ml. 
Indeed at 72hrs, 0.10µg/ml was a better inducer of G2M arrest than a drug 
concentration of 40µg/ml. So 0.02µg/ml vincristine was a potent inducer of 
apoptosis as well as G@M arrest. Increasing the concentration of vincristine up to 
10µg/ml  resulted in less apoptosis at 48hrs and 72hrs (figure 4.5) as well as less 
G2M arrest at 4,6 and 24hrs (figure 4.6) 
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To verify this counter-intuitive finding, low-dose vincristine was compared directly 
with a high concentration of vincristine. Therefore, K562 cells were incubated with 
either 0.1µg/ml or 40 µg/ml of vincristine to take a closer look at cell response to 
this drug. The percentage of apoptosis induced by 0.1µg/ml vincristine was 4.39%, 
7.85%, 10.14% and 18.64% at 24, 48 and 72hrs and 96hrs respectively. At 48 and 
72hrs this was a higher percentage than that induced by 40µg/ml (figure 4.7). The 
greater effectiveness of low-dose vincristine to induce apoptosis was mirrored by a 
greater ability to induce G2M cell cycle arrest (figure 4.8). This is in contrast to the 
response of cells to etoposide where G2M arrest precluded induction of apoptosis. 
 
 
 
 
 
 
 
 
 
 
Najood Omar   110
Effect of low doses vincristine on K562 cells at apoptosis 
 
 
 
 
Figure 4.5: 
Flow cytometry analysis of K562 cell line treated with low doses of vincristine 
ug/ul showing the cells at apoptosis. All test cultures were compared to control 
cultures by unpaired students t-test (result at 24, 48, 72hrs are P<0.05. 
 
 
 
Najood Omar   111
Effect of low dose of vincristine on K562 cells at G2M 
 
 
 
 
Figure 4.6: 
Flow cytometry analysis of K562 cell line treated with low doses of vincristine 
ug/ul showing the cells at G2M phase. All test cultures were compared to control 
cultures by unpaired students t-test (result at 24, 48, 72hrs are P<0.05. 
 
 
Najood Omar   112
 Effect of vincristine on apoptosis in the K562 cells 
 
 
 
 
Figure 4.7:  
Flow cytometry analysis of K562 cells showing the percentage of apoptotic cells 
stained with propidium iodide only. All test cultures were compared to control 
cultures by unpaired students t-test (*P<0.05). 
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Effect of vincristine on induction of G2M arrest in K562 cells. 
 
 
Figure 4.8: 
Flow cytometry analysis of K562 cell line showing the percentage of cells at G2M 
stained with propidium iodide. All test cultures were compared to control cultures 
by unpaired students t-test (*P<0.05). 
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4.3.2 Effect of vincristine on apoptosis in K562 cells by AnnexinV V 
immunostaining:  
 
Annexin V is a cellular protein which has high affinity to phosphotedylserine (PS)  
PS is expressed on the surface of apoptotic cells. (Koopmann et al 1994). K562 cells 
were incubated with vincristine at different concentrations of (0, 0.1, 5, 10, 20, 
40µg/ml) for specific time points (24, 48, 72, 96 hours).    
Harvested cells were stained with Annexin V and propidium iodide and then 
analysed by flow cytometry for detection of apoptosis. Cells binding Annexin V are 
considered apoptotic and exclude propidium iodide. The data in (figure 4.9) of cells 
positive for both parameters does not reflect data generated using the DNA 
technique to determine vincristine-induced apoptosis in figure 27.  However, it does 
support the notion that over a 48hr period there is no large disparity between 
0.1µg/ml and 40 µg/ml, as would be predicted.  
A closer look reveals that there is very little difference in Annexin V binding due to 
vincristine used at either 0.1 or 40µg/ml and this observation is extended to 72hrs 
for this parameter (figure 4.10). However, much of the cell death induced by 
40µg/ml vincristine can’nt be attributed to necrosis since the uptake of propidium 
iodide is greater for this concentration than that of 0.1µg/ml vincristine (figure 
4.11). The apparent loss of propidium iodide uptake in cells at 96hrs (figure 4.11) is 
accounted for, because at this time point necrotic and apoptotic cells are positive for 
both parameters as seen in figure 29. This highlights the limitations of this technique 
for distinguishing between apoptosis and necrosis.  
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Nocodazole, another anti-mitotic agent  confirmed this type of drug  causes G2M 
arrest at low concentrations (figure 4.12) and histone H3 serine 10 phosphorylation 
studies verified that this cell cycle arrest was indeed mitotic (figure 4.13). 
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Effect of vincristine on the rate of apoptosis detected by annexin V staining  of 
K562 cells. 
 
 
Figure 4.9: 
Flow cytometry analysis of K562 cells treated with vincristine and  stained with 
Annexin V  and propidium iodide to study the percentage of apoptotic cells and post 
apoptotic cells  positive of both annexin V and propidium iodide. All test cultures 
were compared to control cultures by unpaired students t-test (*P<0.05). 
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Effect of vincristine on the rate of apoptosis detected by annexin V staining of 
K562 cells. 
 
 
 
 
Figure 4.10:  
Flow cytometry analysis K562 cells treated with vincristine and stained with 
Annexin V only  to study the percentage of apoptotic cells and post apoptotic cells 
that are annexin V positive. All test cultures were compared to control cultures by 
unpaired students t-test (*P<0.05). 
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Effect of vincristine on the rate of apoptosis detected by propidium iodide 
staining in  K562 cells 
 
 
 
 
Figure 4.11:  
Flow cytometry analysis of K562 cells treated with vincristine and stained with 
propidium iodide only to study the percentage of apoptotic cells and post apoptotic 
cells that are propidium iodide positive. All test cultures were compared to control 
cultures by unpaired students t-test (*P<0.05). 
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4.4 Discussion: 
 
This chapter examined the effects of the microtubule inhibitor vincristine on K562 
cells. The initial studies suggested that overall perturbation of the cell cycle and the 
induction of apoptosis followed a similar pattern to that observed for the effects of 
etoposide on myeloid leukemia cell lines. i.e. that the induction of cell death was 
time and drug-concentration dependent. This view was supported by the initial data. 
Over a vincristine drug-concentration range of 5 to 40 ug/ml the induction of 
apoptosis was drug concentration dependent and that the lower concentrations were 
more effective at inducing cell cycle arrest. Thus, like etoposide, cell cycle arrest 
precluded apoptosis. However, the relationship between cell cycle arrest and cell 
death was not so clear as that seen for topoisomersae II inhibitor. Infact, when low-
concentrations of vincristine were studied, which are probably more 
pharmacologically relevant, it was found that over a range of 0.02 to 10ug/ml 
vincristine, the lower concentrations were more effective at inducing apoptosis than 
the higher concentrations. These concentrations were also potent at inducing mitotic 
cell cycle arrest. A direct comparison of 0.01ug/ml with a 400 fold greater 
concentration of 40ug/ml vincristine showed little difference in the induction of 
apoptosis when measure by DNA fragmentation on the flow cytometer. However, 
the lower concentration was much more effective in inducing mitotic cell cycle 
arrest over a 48hr period. An alternative Annexin V binding assay for the detection 
of apoptosis suggested that different mechanisms were at work. The lower 
concentration was as effect at inducing apoptosis as the higher as shown by Annexin 
V binding. However, the higher concentration took up propidium iodide far quicker 
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than the lower, indicative of necrotic cell death. The ability to distinguish between 
apoptosis and necrosis using Annexin V binding at high cell death levels is not 
therefore possible as necrotic cells will also bind Annexin V as the necrotic cell 
permeabilises, a limitation of this technique. 
This observation has connotations. Why is a far lower concentration of vincristine 
as effective as or even better, at inducing apoptosis than a higher drug 
concentration. Also, what is the role of mitotic cell cycle arrest in this process as 
lower concentrations induce mitotic arrest as well as apoptosis when compared to 
control cell cultures. This contrasts with the role of the cell cycle checkpoint at G2 
(just prior to mitosis) induced by etoposide which was seen as a preventer of 
apoptosis. This has clinical relevance since much lower concentrations of vincristine 
may be used thus reducing side effects for patients requiring this treatment with this 
drug. 
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Conclusions: 
High concentrations of vincristine will induce cell death in target cells. 
Lower concentrations of vincristine can be as effective, if not better, than high 
concentrations in inducing apoptosis in myeloid leukaemia cells. 
The induction of apoptosis is associated with a concomitant induction of cell cycle 
arrest at mitosis. 
This suggests that the cell cycle arrest could be inherent to the induction of cell 
death by vincristine. 
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Chapter     5 
 
 
 
Effects of vincristine, etoposide and nocodazole on Cdk1 
phosphorylation and expression of survivin, Aurora B kinase and  
Bax at drug-induced mitosis, G2-arrest and apoptosis. 
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5.1     Introduction: 
Work for this thesis indicates that events just prior to mitosis in G2 and in mitosis 
itself may be important to the mechanisms of cell death induced by etoposide and 
vincristine respectively. One key element of this is the cyclin B/Cdk1 complex, also 
known as the maturation promoting factor (MPF) which drives cells through G2 and 
into mitosis.  In G2 phase of the cell cycle the cyclin B/Cdk1 complex is inactive 
due to an inhibitory phosphorylation of Cdk1 at threonine-14 and tyrosine-15 during 
interphase. The complex is activated by phosphorylation of Cdk1 at threonine-161, 
then for the final activation step it requires dephosphorylation of threonine 14 and 
tyrosine 15 by Cdc25 phosphatase mid G2-phase. Following DNA damage by 
genotoxins or mutations, the ATM/ATR protein kinases will be activated. This 
kinase activity activates Chk1 and Chk2 which in turn phosphorylates Cdc25C at 
S216. This phosphorylation promotes binding of Cdc25C to ∞∞14-3-3 protein 
which thereby sequesters Cdc25C to the cytoplasm and thus prevents it from 
activating nuclear Cdk1. Lack of activated Cdk1 causes cell cycle arrest at G2.  
Activation of Bax, a proapoptotic protein, leads to the release of cytochrome C from 
mitochondria (Chipuk JE et al 2004). So long as Bcl-2 does not negate Bax, by 
forming a Bcl-2/Bax complex, Bax will stimulate the mitochondria to release 
cytochrome C. These events promote apoptosis via the caspase system. 
Survivin, a chromosomal passenger protein also has an anti-apoptotic action. It 
inhibits the apoptotic pathway by inhibiting caspases and is known as an inhibitor of 
apoptosis or IAP protein. Survivin is expressed mainly at G2M phase to protect cells 
from mitotic death during cell division. However, it is constitutively raised in many 
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cancers. An alternative role for survivin is as a passenger protein, where it localizes 
to the spindle microtubules and, together with the other passenger proteins, ensures 
the normal ordered events of mitosis occur. (Kasof  et al 2001).   
The spindle assembly checkpoint (SAC) delays the exit of a cell from the anaphase 
stage of mitosis when chromosomal kinetochore attachment to the spindle is 
inadequate. Correct chromosomal alignment via kinetochores to the mitotic spindle 
leads to destruction of cyclin B by APC proteolysis and that inhibits cyclin B/Cdk1 
activity. The result is an exit of anaphase and eventually an exit from mitosis. 
Prevention of anaphase means cells are held in metaphase if chromosomes are 
incorrectly aligned. However, arrest in metaphase is not permanent and the cell can 
escape mitosis despite an activated spindle assembly checkpoint (Daniela et al 
2006). This process is known as mitotic slippage. 
Vinca alkaloids are powerful antitumor drugs which inhibit cell division at mitosis 
by their action on microtubules. Vincristine damages tubulin. They   prevent the 
action of microtubules by inhibiting polymerization of tubulin and causing 
depolymerisation of already formed tubules (Jordan et al 1986, 1991).  
A low dose of nocodazole, a non-clinically used anti-mitotic agent, also alters the 
microtubule dynamics, arresting the cells in mitosis. A high dose of nocodazole also 
prevents progression of the cells into full mitosis because of rapid depolymerisation 
of microtubules. This can causes apoptosis. (Vasquez et al 1997). 
Etoposide on the other hand is a topoisomerase 2 inhibitor.  Inhibition of this 
enzyme allows damaged DNA to persist and arrest the cell at G2 phase even in low 
doses. 
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5.2    Aims:  
-To study the relation between the chromosomal passenger protein survivin and the 
spindle assembly checkpoint. 
-To study the relationship between the apoptotic protein Bax and the spindle 
assembly checkpoint. 
-To study the relation between Cdk1 phosphorylation status and the spindle 
assembly check point. 
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5.3    Results: 
5.3.1     Effect of vincristine on Cdk1 expression and survivin      expression in 
K562 cells: 
 In the last chapter it was established that 0.1ug/ml vincristine induced mitotic cell 
cycle arrest followed by apoptosis whereas the higher concentration induced a 
combination of apoptosis and necrotic markers without cell cycle arrest in the K562 
cell line. To shed some light on the mechanisms of cell cycle arrest the expression of 
the pivotal G2/mitotic kinase was investigated at both low and high concentrations of 
vincristine. The expression of Cdk1 remained constant over a 72 hr period for both 
drug concentrations when compared to the control no matter whether the cells had 
been incubated with 0.1 or 40ug/ml vincristine. However, 0.1ug/ml vincristine 
induced expression of survivin when compared to the control which was not seen with 
the higher drug concentration (figure 5.1).  
One of the regulatory elements of Cdk1 activity is its phosphorylation status at 
tyrosine 15. Using an anti phosphotyrosine antibody specific to Cdk1-Y15, it was 
established that there was an apparent tyrosine phosphorylation of Cdk1 with both 
drug concentrations over a 72 hr period. However, there was a small but gradual 
reduction of this phosphorylation over time at the lower drug concentration (figure 
5.2).This slight reduction in phosphorylation status was also seen when cells were 
incubated with 40µg/ml vincristine. Pro-apoptotic Bax was also induced by 
vincristine at both concentrations  when compared to control (figure 5.3) 
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Effect of vincristine on expression of Cdk1 and survivin  at G2M arrest and 
apoptosis in K562 cells. 
 
 
                                                                                                                             
40 µg/mL 0.1 µg/mL 
 
WCL      a) 
 
    Cdk1 WCL      b) 
    Survivin 
WCL      c)  β ‐actin  
 
Figure 5.1: 
a)Western blot of whole cell lysates of K562 cells treated with vincristine at 
different doses and different length of time, have been immunostained for Cdk1, 
survivin and β –actin as control. 
  
 Lane 1 control cell.  
 Lane 2 vincristine of  0.1  µg/ml for 24 hours.  
 Lane 3 vincristine of  0.1  µg/ml for 48 hours.  
 Lane 4 vincristine of  0.1 µg/ml for 72 hours.  
 Lane 5 vincristine of  40  µg/ml  for 24 hours.  
 Lane 6 vincristine of  40  µg/ml  for 48 hours.  
 Lane 7 vincristine of  40  µg/ml for 72 hours.  
  b) The same membrane stained for survivin. 
 c) The same membrane stained for β-actin. 
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Effect of vincristine on G2M arrest and apoptosis  phosphorylation of tyrosine 
15 on Cdk1 in K562 cells 
 
 
 0.1 µg/mL  40 µg/mL  
 
      C      24h       48h      72h        24h    48h      72h 
 
WCL      a) 
 Tyrosine 15 
 
β ‐actin WCL      b) 
 
Figure 5.2: 
a) Western blot of whole cell lysates of K562 cells treated with vincristine at different 
doses and different times then immunostained for Cdk1 phosphorylated at tyrosine 
15. 
 
Lane 1 control cell.  
Lane 2 vincristine 0.1µg/ml at 24 hour. 
Lane 3 vincristine 0.1 µg/ml for 48 hours. 
Lane 4 vincristine 0.1 µg/ml for 72 hours. 
Lane 5 vincristine 40 µg/ml for 24 hours.  
Lane 6 vincristine 40 µg/ml for 48 hours. 
Lane 7 vincristine 40 µg/ml for 72 hours. 
        b)   Same membrane stained for β-actin. 
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Effect of vincristine on G2M arrest and apoptosis for expression of Bax in 
K562   
Cells. 
 
                      0.1 µg  40 µg 
 
C       24H   48H   72H     24H   48H    72H
       
 
WCL     A)  Bax 
 
 
β ‐Actin 
 
WCL     B) 
 
Figure 5.3: 
                           A) Western blot of whole cell lysate of K562 treated with vincristine at different 
doses and different time points, stained for Bax and β-actin. 
 
       Lane 1 control cells  
       Lane 2 vincristine 0.1µg/ml for 24 hour, 
       Lane 3 vincristine 0.1µg/ml for 48 hours, 
       Lane 4 vincristine 0.1µg/ml for 72 hours,  
       Lane 5 vincristine 40 µg/ml for 24 hours, 
       Lane 6 vincristine 40 µg/ml for 48 hours,  
       Lane 7 vincristine 40 µg/ml for 72 hours stained for Bax. 
B)   Same membrane immunostained for β-actin. 
 . 
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5.3.2 Further analysis of the effects of vincristine on Cdk1phosphorylation status in 
K562 cells:    
To analyse further the phosphorylation status of Cdk1 during incubation of cells 
with vincristine it was decided to look at Cdk1 expression and its phosphorylation 
status by immunoprecipitation. K562 cells were treated with vincristine of 0.1 and 
40µg/ml at 24, 48, 72 hours as before. Protein extraction was done after flow 
cytometry analysis at each dose and at the time points indicated. 
Cdk1 was immunoprecipitated and the immunoprecipitated protein lysate was 
analysed by gel electrophoresis, then transferred onto PVDF membranes which 
were immunostained with anti-phosphotyrosine antibody, then stripped and 
restrained with an anti-phospho-Y15 Cdk1 antibody (Figure 5.4). 
Cdk1 tyrosine phosphorylation was readily detected in control cells and cells 
incubated with 0.1µg/ml vincristine for 24 and 48hrs. By 72 hrs, when apoptosis 
was detectable, there was a reduction in phosphotyrosine residue expression. The 
high-concentration vincristine produced a similar loss of tyrosine phosphorylation 
but this was seen earlier at 48hrs using this drug concentration as well as at 72hrs. 
However these two longer cultures for 48 and 72 hours show higher rates of 
apoptosis than that observed at 24 hours. Thus a loss of Cdk1 tyrosine 
phosphorylation was detected at time points or drug concentrations that induce 
apoptosis. The data suggests that the changes in tyrosine phosphorylation can be 
attributed to tyrosine 15 as the total tyrosine phosphorylation has the same pattern of 
expression as that for tyrosine 15 phosphorylation (figure 5.4). 
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Effect of vincristine on tyrosine phosphorylation status of Cdk1 at G2M arrest 
and apoptosis in K562 cells 
 
a)  Cdkl IP Tyrosine 15                                                                                  
b)  Cdkl IPTotal Tyrosine 
                                                                            
 
Figure 5.4: 
a) Immunoelectrophoresis of immunoprecipitated Cdkl from whole cell lysates of 
K562cells treated with vincristine of different doses for different time points 
immunostained for total tyrosine phosphorylation  
 
Lane 1 control cells.                       
Lane 2 vincristine 0.1µg/ml for 24 hours.  
Lane 3  vincristine 0.1µg/ml for 48 hours.  
Lane 4  vincristine 0.1µg/ml for 72 hours. 
Lane 5  vincristine 40µg/ml for 24 hours. 
Lane 6  vincristine 40µg/ml for 48 hours.   
Lane 7  vincristine 40µg/ml for 72 hours. 
      b)    Same membrane re-stained for Tyrosine 15 phosphorylation. 
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 Effect of vincristine on phosphorylation status of Cdk1 bound to cyclin A at 
G2M arrest and apoptosis in K562 cells  
 
                              1       2     3     4       5      6     7                                      
                         
   
 
a)  i.p.Cyclin A  
 
 Tyrosine 15  
b) i.p.Cyclin A  Total Tyrosine 
 
Figure 5.5:  
   a) Immunoelectrophoresis of Cdk1 that immunopreciptated with cyclin A from 
whole cell lysate of K562cells treated with vincristine of different doses at different 
time points then  immunostained for total tyrosine phosphorylation of Cdk1 .  
               Lane 1 Control.  
               Lane 2 vincristine  0.1µg/ml  for 24 hours.  
               Lane 3  vincristine  0.1µg/ml  for 48 hours.  
               Lane 4  vincristine  0.1µg/ml  for 72 hours. 
               Lane 5  vincristine  40µg/ml   for 24 hours. 
               Lane 6  vincristine  40µg/ml   for 48 hours.   
               Lane 7  vincristine  40µg/ml    for 72 hours. 
        b)   Same membrane stained for tyrosine 15 phosphorylation 
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The majority of  Cdk1 is bound to cyclin B. However, a small proportion also binds 
to cyclin A, the cyclin associated with transition through S-phase and the initial 
entry into G2. My group has published data associating changes in tyrosine 
phosphorylation with etoposide-induced cell death that was not related to tyrosine 
15. This was achieved by examining Cdk1 in cyclin B depleted lysates of etoposide 
treated cells and looking at the phosphorylation status of Cdk1 that co-precipitates 
with cyclin A.(Higginbottom et al 2007) 
 To determine whether this phosphorylation was apparent in vincristine-induced cell 
death, K562 cells were incubated with 0.1 and 40µg/ml of vincristine for 72 hrs and 
the phosphorylation status of Cdk1 that co-precipitated with cyclin A was examined 
(figure 5.5) 
The data contrasted to that presented in figure 36, where the reduction of overall 
phosphorylation reflected the reduction of tyrosine 15 phosphorylation. In this 
experiment the reduction of tyrosine phosphorylation associated with prolonged 
incubation of cells with 0.1 µg/ml vincristine (lanes 3 and 4, figure 5.5) or all time 
periods with 40 µg/ml (lanes 5-7) was not reflected by a loss of overall tyrosine 
phosphorylation on the Cdk1 associated with cyclin A (figure 5.5). The degree of 
tyrosine 15 phosphorylation detected after 24hrs of 0.1 µg/ml vincristine (lane 2) 
was the same as the control. However, after 72hrs a clear reduction of tyrosine 15 
phosphorylation could be seen (lane 4). Also, 40 µg/ml caused a reduction in 
tyrosine 15 at all time points (figure 5.5). However, there was no change in overall 
tyrosine phosphorylation relative to control. This indicates the loss of 
phosphorylation seen on cyclin A-associated Cdk1 is associated with tyrosine 15 in 
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cells primed to die via vincristine. The fact that this is not reflected in the overall 
tyrosine phosphorylation of cyclin A associated Cdk1 opens the possibility that 
there is an addition compensatory tyrosine phosphorylation of cyclin A-associated 
Cdk1 in dying cells as reported by my group for etoposide.  Thus a different 
tyrosine phosphorylation pattern is seen on Cdk1 bound to cyclin A to that seen on 
Cdk1 bound to cyclin B when cells are incubated with vincristine to cause cell 
death.  
This is not an antibody phenomenon since the same antibodies were used to follow 
tyrosine phosphorylation shown in figure 36 where the two antibodies showed 
concordance     
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5.3.3. Effect of etoposide and nocodazole on survivin expression in K562 cells. 
The investigation into the effects of vincristine on K562 cells at G2M suggested that 
a drug concentration that induced cell cycle arrest was associated with induction of 
the cell survival protein survivin, which was not induced at high drug concentrations 
when compared to controls. To determine if this was also true for the DNA-
damaging agent etoposide, the induction of survivin was examined in K562 cells 
following incubation with low and high-dose etoposide. Nocodazole, a non-clinical 
anti-mitotic agent, was used to compare events at G2 (low dose etoposide) with 
mitotic events (low dose nocodazole).  
PAGE and Western blotting were performed on lysate of K562 cells to determine 
the effect of etoposide and nocodazole on survivin expression at G2M arrest and 
apoptosis, and the relationship of Cdk1 with survivin at the same stages of the cell 
cycle. 
The results show similar expression of survivin by cells treated with etoposide at 
doses which cause G2 arrest and by doses that cause apoptosis at 24 hours. 
Exposure of the cells to the same doses for 48 hours caused very little change in 
expression of survivin (figure 38). Nocodazole, which is a mitotic inhibitor like 
vincristine, also had little effect on survivin expression at concentrations that cause 
mitotic arrest.  
The relationship of survivin with Cdk1 was then examined. Figure 33 had shown 
loss of survivin in lysates from cells induced to die by vincristine but not in those 
induced to undergo mitotic arrest. Mitotic cell cycle arrest was induced in K562 
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cells by nocodazole and compared to the effects of etoposide at a concentration that 
also induces cell cycle arrest. The data shows that expression of survivin is 
maintained in K562 cells in both G2 arrest (etoposide) and in mitotic arrest 
(nocodazole). Moreover, it immune-precipitates with Cdk1 in both situations. 
However, survivin no longer immuno-precipitates with Cdk1 when etoposide is 
increased to a apoptosis-inducing concentration. Interestingly, Aurora B kinase, a 
protein that interacts with survivin when survivin functions as a mitotic passenger 
protein does not co-precipitate with Cdk1 at either low or high concentrations of 
etoposide (figure 5.7). However, survivin and Aurora B were shown to co-
precipitate with each other, in the absence of Cdk1 when cells were incubated with 
etoposide or low-dose nocodazole. This was shown by an immuno-precipitation of 
survivin followed by gel electrophoresis and staining the resulting western blot for 
Aurora B kinase (figure 5.8).   
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Effect of etoposide and nocodazole on the expression of survivin in K562 cells. 
 
 
 
                                  1        2          3         4           5        6         7        8  
                                                                                                                                                                     
a)  Survivin                                                                                                                        
b) β-actin      
  
 
 Figure 5.6: 
a) I
immunoelectrophoresis of whole cell lysates of K562 cells treated with 
etoposide and nocodazole, and immunostained for survivin. 
 
          Lane 1 control cell. 
          Lane 2 nocodazole    0.1 µg/ml    for 24hours. 
          Lane 3 etoposide      0.1  µg/ml    for 24 hours.  
          Lane 4 etoposide      40   µg/ml    for 24 hours. 
          Lane 5 control cells.  
          Lane 6 nocodazole   0.1   µg/ml for 48 hours.  
          Lane 7 etoposide      0.1   µg/ml for 48 hours. 
          Lane 8 etoposide      40    µg/ml for 48 hours.              
    b)  Same membrane immunostained for β-actin 
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 Effect of etoposide on apoptosis and expression of chromosomal passenger 
proteins in relation to Cdk1 in  
K562 cells at G2M arrest. 
 
                                                                    
                                            1         2        3        4      
                                                                                       a) Aurora B 
 
                                                                                        b) Survivin                                                            
 
Figure 5.7: 
a) Immunoelectrophoresis of whole cell lysates of K562 cells, and treated with 
etoposide and nocodazole at apoptosis and G2M arrest, immunoprecipitated for 
Cdk1 and stained for Aurora B.  
 
   Lane 1   control cell. 
   Lane 2   nocodazole 0.1µg/ml for 24 hours. 
   Lane 3   etoposide   0.1 µg/ml for 24 hours.   
   Lane 4   etoposide   40 µg/ml  for 24hours. 
           b)   Same membrane immunostained for Survivin. 
 
 
 
 
 
Najood Omar   139
Effect of etoposide and nocodazole on the co-precipitation of Aurora B kinase 
with survivin in K562 cells. 
 
 
                                 24hrs                               48hrs 
                       1        2        3       4      5       6       7        8  
                    
 
              Figure 5.8: 
          Lane 1 control cell. 
          Lane 2 nocodazole    0.1 µg/ml    for 24hours. 
          Lane 3 etoposide      0.1  µg/ml    for 24 hours.  
          Lane 4 etoposide      40   µg/ml    for 24 hours. 
          Lane 5 control cells.  
          Lane 6 nocodazole   0.1   µg/ml for 48 hours.  
          Lane 7 etoposide      0.1   µg/ml for 48 hours. 
          Lane 8 etoposide      40    µg/ml for 48 hours.              
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5.4 Discussion: 
Work in previous chapters had shown some fundamental differences in the response 
of cells to a DNA damaging agent (etoposide) and an anti-mitotic agent (vincristine) 
in the relationship between cell cycle arrest and cell death.  
Data presented in this chapter shows that vincristine will induce the anti-mitotic 
protein survivin, at concentrations that induce mitotic cell cycle arrest followed by 
apoptosis, but not at concentrations that induce cell death directly It has no effect on 
Cdk1 expression although tyrosine phosphorylation of Cdk1 is diminished under 
conditions that induce cell death. Interestingly, vincristine induced Bax as though 
priming the cell for cell death at all concentrations.. A closer look at Cdk1 tyrosine 
phosphorylation indicated the loss of phosphorylation was on the regulatory tyrosine 
15 residue. However, the proportion of Cdk1 that binds cyclin A, rather than cyclin 
B may have other phosphorylation responses as overall tyrosine phosphorylation 
was not affected by vincrisitine, although tyrosine 15 phosphorylation was again 
reduced on induction of death in target cells. 
Etoposide on the other hand caused a slight increase in survivin expression at all 
drug concentrations and time points. Cdk1 co-precipitated with survivin in control 
cells and with a drug concentration that induced G2 cell cycle arrest (0.1µg/ml) but 
not with a higher drug concentration that induced apoptosis (40µg/ml). This 
suggests that Cdk1 can target survivin for phosphorylation under non-fatal 
conditions. Interestingly, another passenger protein Aurora B did not co-precipitate 
with Cdk1 under conditions of either cell cycle arrest or cell death which may 
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suggest survivin is acting as an IAP in these circumstances and not as a passenger 
protein.       
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5.5       Conclusions 
 
Vincristine does not alter the expression of Cdk1 
 
Low-concentration vincristine (0.1µg/ml) induces survivin expression but a higher 
concentration (40µg/ml) does not induce it. 
 
A slight reduction in Cdk1 tyrosine 15 phosphorylation was detected in whole cell 
lysates in association with vincristine-induced cell death i.e. cells incubated with 
0.1µg/ml for 48 to 72 hrs and 40 µg/ml  at all time points.  
 
Closer inspection of Cdk1 immuno-precipitates confirmed this observation on Cdk1. 
 
The overall tyrosine phosphorylation of Cdk1 bound to cyclin A did not diminish under 
the conditions cited above although some loss of tyrosine 15 phosphorylation was 
detected. It may be a possibility that there is some further phosphorylation of Cdk1 
bound to cyclin A in cells induced to die. 
 
Vincristine may prime cells for apoptosis by augmenting Bax expression.. 
 
Unlike vincristine, etoposide had little effect on survivin expression. 
 
Survivin co-precipitates with Cdk1 in cells in G2-arrest but not in cells induced to die. 
Aurora B, another passenger protein, does not co-precipitate with Cdk1 in either 
etoposide-arrested cells nor in cells induced to die. 
 
Survivin and Aurora B are found to co-precipitate in cells incubated with low (G2 
arrest) and high-concentration (apoptosis) etoposide.  
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6.1     Introduction: 
Cancer chemotherapy damages cells in various ways and some of this damage 
activates the cell cycle checkpoints. Checkpoint activation causes cell cycle arrest 
and triggers repair mechanisms. When cell repair cannot be achieved, cell death 
usually occurs. However, within intact animals and tissues, cells are heterogeneous. 
Therefore, one way of studying the detailed responses of cells to damage is to 
isolate them in culture (Clarke  et al, 2006).  
The cultured K562 and HL60 cells used in these experiments are human myeloid 
leukemia cell lines. Both cell lines are p53 negative but the former also contains the 
Bcr-Abl fusion gene created by the chromosomal translocation that forms the 
Philadelphia chromosome. A combination of p53 negative and Bcr-abl positive 
contributes towards a delay in apoptotic responses in this cell line allowing a 
window of opportunity to investigate cell death responses to cellular insult. Multiple 
genetic events are required to establish immortal cell lines. This means that results 
of studies of such cell lines should be interpreted with caution. However, in the 
present work similar results were obtained from these two similar cell lines 
strengthening the validity of the experiments and enabled one of them (K562 cells)  
to then be used for subsequent experiments (Martin et al, 1997).  
DNA can be directly damaged by anticancer treatment; alternatively, DNA repair 
enzymes such as topoisomerase 2 can be inhibited by drugs such as etoposide. 
Inhibition of DNA repair enzymes enables faults in DNA replication to persist. 
Detection of this DNA damage in turn stimulates the DNA damage checkpoints, 
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resulting in stimulation of p53 gene expression. p53 is a transcription factor and is 
the most important tumor suppressor gene. p53, ‘the guardian of the genome’ helps 
to repair DNA damage by arresting cells at G1 phase while repair mechanisms are 
activated. However, because K562 and HL60 are p53 gene deficient, the lack of p53 
expression causes an activation of the Chk1 kinase pathway that arrests the cells at 
G2 phase (Levesque AA et al 2008). The other class of chemotherapeutic drugs 
used in these experiments, vincristine and nocodazole, are microtubule damaging 
agents which stimulate the spindle assembly checkpoint, an important antitumor 
target. Thus, knowledge of the specific in vitro responses of cancer cells to 
therapeutic agents will reflect the fate of target cells in treated patients. Events at the 
G2 checkpoint and in mitosis have now been shown to determine cell survival or 
cell death particularly in p53 compromised cells(Gomes et al, 2010).  
Between these two cellular outcomes is cell cycle arrest. Depending on the 
response, cells may die either by apoptosis or by mitotic catastrophe. Alternatively, 
the cell may revert into the cell cycle, perhaps with abnormal chromatin containing 
uncorrected DNA damage or other abnormalities (Sun et al, 2009). 
In my experiments in p53 deficient cells which are resistant to apoptosis, the cells 
responded in different ways to damage. Levels of apoptosis and cell cycle arrest 
varied with both treatment doses and treatment duration as described below. 
 
 
 
Najood Omar   146
6.2      Effects of cytarabine and etoposide on the cell cycle of K562 cells:  
In my experiments the effects of cytarabine were not dose related probably because 
cytarabine is converted by an enzyme to an active form and this rate of conversion 
constitutes a rate limiting step. Thus, increasing doses of cytarabine had no 
additional effect on the cells probably because the rate of conversion to the active 
form remained steady, in spite of increasing doses of the precursor. An alternative 
possibility is that one of the mechanisms which leads to cell death is a rate limiting 
factor. This is less likely since other drugs such as etoposide which also induce 
apoptosis have dose related effects. The effect of cytarabine contrasts with the dose 
related action of etoposide which acts directly and does not require enzyme 
conversion to an active form (Loughlin et al, 1996). 
The effects of etoposide on K562 cells were analysed by flow cytometry. The 
technique showed that etoposide treatment induced prolonged G2 arrest.  However, 
the highest doses of etoposide also caused apoptosis. These findings confirm other 
experiments . There is more than one possible explanation: first, the cells resist the 
effects of low doses by compensatory mechanisms which may be overcome with 
higher doses. Alternatively, the cells could have a lower threshold for G2M arrest, 
while higher doses activate different mechanisms possibly with a higher threshold 
and cause apoptosis. 
 Low doses cause cell cycle arrest; high doses cause apoptosis, and the higher the 
dose of etoposide, the more apoptosis is induced.  Both of these observations have 
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important implications for the treatment of leukaemia patients by chemotherapy. 
Etoposide caused similar changes in HL60 cells. 
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   6.3     Effect of etoposide and nocodazole studied by immunostaining H3Ser10: 
Studies of the four core histone proteins (H1-H4) have shown that phosphorylation 
of Ser10 on histone H3 is associated with chromosomal condensation during mitosis 
(Hendzel et al, 1997). Therefore phosphorylation of Ser 10 on H3 is an indicator for 
mitosis.  Immunostaining cells with H3Ser10 antibody confirmed that the 
percentage of cells in mitosis was very low, confirming that the arrested cells were 
restricted to G2 phase arrest. Therefore HL60 cells treated with etoposide showed 
high levels of G2 arrest which occurred by 24hours. The H3Ser10 data show that 
etoposide induces G2 arrest and not mitotic arrest. DNA strand breaks are not 
reunpaired during topoisomerase 2 inhibition. DNA damage therefore will stimulate 
Chk1 which phosphorylates Ser216 on Cdc25C. This deactivates cyclin B/Cdk1 as 
part of the involvement of the G2M checkpoint (Williams et al, 2001).  
DNA damage increases Cdk1 phosphorylation and decreases the activity of cyclin 
B/Cdk1 complex (Zhang et al, 2009). This may causes either G2M arrest or an 
abnormal mitosis. Escape from mitosis may allow the cells to enter G1 phase at the 
border of the G1 checkpoint. This accumulation of cells with abnormal DNA in G1 
phase may induce apoptosis. This is caused by p21 activation and mediated by Bax, 
a proapoptotic protein (Maddika et al, 2007). We confirm here that this activation of 
apoptosis prevents damaged cells from entering the cell cycle.  
Etoposide induces G2M arrest precisely at G2 phase. This was confirmed by lack of 
H3Ser10 antibody staining which showed that the cells had not entered mitosis. 
Thus any lethal effect of etoposide does not occur during mitosis. The cells 
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accumulate at the border of G1-phase and the lethal effect is probably due to mitotic 
slippage which stimulates apoptosis.  
The conclusions from this work are that G2 cell cycle arrest and apoptosis do not 
occur together in   either K562 or HL60 cells. When there is G2 cell cycle arrest, 
apoptosis does not occur. The results suggest that cells can escape G2-arrest and 
mitotic arrest, the latter probably by mitotic slippage. When apoptosis occurs there 
is no cell cycle arrest. Thus cell death induced by etoposide post G2 arrest is due 
predominantly to apoptosis. Evidence that entry into, and out of, mitosis may be 
responsible for the induction of apoptosis will be discussed in a following section. 
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6.4     Effects of antimicrotubule agents on K562 cells: 
Vinca alkaloids such as vincristine are used in human cancer treatment. They inhibit 
microtubule assembly by depolymerising microtubules. This prevents formation of 
the metaphase spindle. The abnormal metaphase spindle prevents attachment of the 
microtubules to the kinetochores on the chromosomal centromeres. This failure of 
attachment arrests the cell at mitosis. Prolonged mitotic arrest causes cells to 
accumulate in prometaphase as a consequence of mitotic checkpoint signalling from 
unattached kinetochores. Continued treatment with vincristine leads to cell 
death(Lentini et al, 2008). 
Short term drug treatment can cause sustained mitotic arrest until the drug is 
cleared. This mechanism of action is cytostatic, with renewed cell cycling after drug 
removal. The second outcome is adaptation in which cells exit long term mitotic 
arrest while still exposed to the drug. In this case cytokinesis fails but the cells still 
enter G1. Adapting cells could escape to G1 then continue dividing despite 
continued mitotic checkpoint signalling.  The inappropriately elevated levels of 
checkpoint inhibitors then provoke apoptotic death in interphase (Moore et al, 
2009). A final outcome is activation of a death pathway from mitosis. Cell death by 
apoptosis following such long term arrest is mediated by caspase dependent 
pathways accompanied by activation of Bax (Beth et al, 2005) 
My data show that the effects of vincristine are both concentration and time 
dependent. Low-doses of vincristine induced G2M arrest that was subsequently 
associated with apoptotic cell death. Interestingly, high doses appear to induce less 
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G2M arrest which was associated with necrotic death rather than apoptosis. This is 
in contrast to the etoposide data which show that low doses cause G2 arrest and high 
dose induce cell death. Thus, disparity between the disproportionately high levels of 
G2M arrest and low levels of apoptosis induced with high dose vincristine may be 
explained by low doses causing enough microtubule damage to cause cells to 
undergo G2M arrest. Some of these cells will subsequently undergo apoptosis. 
Higher doses which cause more microtubule damage will also cause G2M arrest, 
but the microtubules may be too damaged to allow cells to undergo either mitotic 
slippage or apoptosis even though there is activation of proapoptotic mechanisms as 
shown by raised annexin V immunostaining by flow cytometry and high expression 
of Bax by western blotting.  
The spindle assembly checkpoint delays the exit of a cell with inadequately attached 
kinetochores, or lack of spindle tension, from mitosis. Destruction of cyclin B by 
APC proteolysis inhibits cyclin B/cdk1 activity (Perera et al, 2007). This will allow 
the cell to escape mitosis in the presence of an uncompleted spindle assembly 
checkpoint (Daniela et al, 2006). In other opinions depletion or lack of accumulation 
of active chromosomal passenger complex in centromeres at mitosis leads to 
premature exit from mitosis  accompanied by the loss of  Mad2 and Bub1 from 
unattached kinetochores (Stoepel et al, 2005).  Reduction of any one of the 
chromosomal passenger constituents by any means triggers the concurrent 
elimination and mis-localization of the others. (Caravalho et al, 2003). However, 
another possibility is that activation of the spindle assembly checkpoint may itself, 
be responsible for the induction of apoptosis at mitosis under these circumstances 
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6.5  Effect of microtubule and DNA damage on Cdk1 phosphorylation status and 
associated chromosomal passenger proteins at G2M, mitosis and apoptosis. 
 
An attempt was made to understand the underlying mechanisms for the observations 
made. The work for this thesis has shown that low-concentration vincristine caused 
mitotic arrest which was then followed by apoptosis. This introduces the concept of 
mitotic slippage and the possibility that mitotic arrest, or activation of the spindle 
assembly checkpoint, is required for the apoptotic response. 
The data in chapter 5 indicated that low-concentration vincristine induced survivin 
expression whereas high concentrations did not induce survivin expression. This 
suggests a survival signal is induced at these lower concentrations. Also all 
concentrations of vincristine induced enhanced expression of pro-apoptotic Bax, 
suggesting that the cells become primed to die and will do so in the absence of a 
survival signal such as survivin.The reduction in tyrosine 15 phosphorylation seen 
in vincristine-treated cell is in agreement with the concept of Cdk1 activation during 
entry into mitosis. However, active Cdk1 also supports the notion that survivin may 
be acting as a substrate for Cdk1. This is important because Cdk1 phosphorylation 
of survivin at Thr34 enables survivin to sequester caspases and hence block caspase-
mediated apoptosis (Temme et al,2003). This is supported by the observation that 
Cdk1 co-precipitated with survivin when leukaemia cells were incubated with 
another mitotic spindle inhibitor, nocodazole (figure 5.7), Thus the initial response 
of K562 leukaemia cells to low-concentration vincristine is to establish a pro-
survival signal through induction of survivin expression; de-phosphorylated (and 
hence active) form of Cdk1 is observed raising the possibility of caspase 9 
Najood Omar   153
sequestration at the time of the mitotic cell cycle arrest seen in chapter 4 (Allan  et 
al, 2009). Pro-apoptotic Bax is present throughout these events but my data cannot 
distinguish whether this is the active form or the inactive form of Bax.The literature 
states that in other cell systems, Bax becomes activated after activation of mitotic 
spindle assembly checkpoint(Wong et al, 2008). Hence the death or survival of a 
leukaemia target cell in response to vincristine depends upon a balance between 
survival signaling as a result of an induction of survivin expression, its 
phosphorylation by an active mitotic Cdk1/cyclin B complex and sequestration of 
caspases on one hand and the induction of activated pro-apoptotic Bax by the 
spindle assembly checkpoint on the other hand (Thomadaki et al, 2009). 
These data relating to low-dose vincristine are more relevant to the physiological 
situation, as the combination of apoptosis and cell death seen with high-
concentration vincristine would not be tolerable in vivo. 
Some of this data for vincristine contrasts with that observed for etoposide. As 
etoposide targets DNA, it activates the G2 DNA damage checkpoint brought about 
by a predicted inhibition of Cdk1 activity via tyrosine/threonine phosphorylation or 
cytosolic sequestration of the Cdk1/cyclin B complex. Cells did not enter mitosis 
(unlike mitotic cell cycle arrest induced by vincristine where Cdk1 is active). Low-
dose etoposide-induced Cdk1 tyrosine phosphorylation has been shown by other 
workers in my group (Higginbottom et al, 2002). However, in common with the 
mitotic cell cycle arrest induced by the microtubule inhibitor nocodazole, survivin 
co-precipitated with Cdk1 during an etoposide-induced G2 arrest indicative of a 
survivin-mediated sequestration of caspase 9 thus promoting a status of cell survival 
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during cell cycle arrest. An interesting contrast between mitotic cell cycle arrest and 
G2 cell cycle arrest was the additional co-precipitation of Aurora B kinase with 
Cdk1 and survivin with the former agent (figure 39). Also of interest was that when 
the concentration of etoposide was increased to a cell death-inducing concentration, 
neither survivin nor Aurora B co-precipitated with Cdk1. 
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6.6  Is there a common pathway between DNA damaging agents and microtubule 
assembly inhibitors in killing p53 negative leukemia target cells. 
 
The data in this thesis has utilised two agents used to treat neoplasia, one targeting 
DNA and the other targeting mitotic tubule assembly. Both drugs induce cell cycle 
arrest at relatively low drug concentrations. Etoposide induces a cell cycle arrest at 
G2 and vincristine induces a mitotic cell cycle arrest.  However, the cell cycle arrest 
induced by etoposide protects cells from apoptosis whilst the mitotic arrest induced 
by vincristine appears to be required for a later induction of apoptosis. In both 
scenarios, survivin provides the initial survival signal during cell cycle arrest.  
How vinca alkaloids such as vincristine induce apoptosis is still not known. 
However, activation of the spindle checkpoint along with a transient  delay in cell 
cycle progression is required (Thomadaki et al, 2009). Cdk1/cyclin B is active until 
late anaphase (Hershko  et al, 1999). My data show induction of survivin expression 
and a potential role for Aurora B and survivin, possibly as mitotic passenger 
proteins, in maintaining the temporary checkpoint until Bax activation. Several 
examples of cell death after mitotic adaptation implicate Bax in the pro-apoptotic 
response. 
Some of these events may facilitate etoposide-induced apoptosis in p53 
compromised cells. Data from chapter 4 indicates that cell death is associate with a 
collapse of the post S-phase checkpoints (G2 and mitotic checkpoints) on induction 
of apoptosis. To induce Bax activation in p53 negative cells following drug-induced 
DNA damage, Vogel et al have suggested that a balance occurs between the mitotic 
checkpoint protein Mad2 on the one hand, and survivin and Aurora B kinase on the 
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other. They used an agent called UCN-01 which inhibits Chk1 and thus prevents 
accumulation of cells at the G2 checkpoint in the presence of DNA damage. Chk1 
induces the G2 checkpoint in the presence of DNA damage by inactivating Cdc25 
(Vogel et al, 2007). Cdk1/cyclin B remains phosphorylated and thus inactive in this 
situation causing cell cycle arrest. Inhibition of Chk1 has the opposite effect; Cdc25 
remains active in the presence of DNA damage, thus Cdk1/cyclin B remains active 
and cells enter mitosis. The authors showed that the ensuing apoptosis, seen as a 
result of cells with drug-induced DNA damage entering mitosis, was dependent on 
the spindle checkpoint protein Mad2. Mad2-induced apoptosis is in turn dependent 
on activation of the spindle checkpoint that also requires the passenger protein 
Aurora B kinase and the passenger protein function of survivin. However, survivin 
can act as an anti-apoptotic protein when phosphorylated on thr 34 by sequestering 
caspase 9. Vogel et al were also able to show that cell death induced by DNA 
damage in cells that entered mitosis as a result of treatment with UCN-01 could be 
sensitized to enhanced apoptosis in this model by shRNA interference of survivin, 
or by chemical inhibition of Aurora B kinase. The proposed mechanism being that 
survivin is responsible for a stabilization of Bcl-2 through phosphorylation of Bcl-2 
and a subsequent prevention of Bax activation. Presumably active Aurora B kinase 
stabilises survivin; it is also known that Cdk1 activity stabilizes survivin so 
inhibition of Cdk1 and/or Aurora B kinase contributes to the pro-apoptotic signal 
(Vogel et al,2007) . 
 Thus it is feasible that both vincristine and etoposide could share a common and 
potentially synergistic activation of Bax in mitosis. 
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My data has also highlighted a novel aspect to these events. Figure 5.5 shows that 
the total tyrosine phosphorylation of Cdk1 bound to cyclin A, rather than cyclin B, 
does not reflect that of tyrosine 15 when cells were incubated with vincristine. This 
suggests that cyclin A-associated Cdk1, under conditions that induce apoptosis after 
mitotic arrest (0.1µg/ml for 72hrs), and that induced by high-concentration 
vincristine, is phosphorylated on residues other than tyrosine 15. This has the 
potential to change Cdk1/cyclin A activity or substrate. These data substantiate that 
published by our group for etoposide- induced  apoptosis (Higginbottom  et al, 
2002).   
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   6.7     Concluding Remarks and Future Directions: 
The data in this thesis and the accompanying review of the literature have attempted 
to highlight the importance of the G2 and M phases of the cell cycle in leukaemia 
cell chemotherapy of p53 negative cells. In the absence of the “guardian of the 
genome” the G2 and mitotic phases of the cell cycle and their inherent checkpoints 
should be major targets for exploitation by therapeutic agents.   
It is desirable to reduce the toxicity of common anti-cancer agents such as etoposide 
and vincristine, by reducing their active concentrations. It is also desirable to 
enhance the efficiency in which drugs kill target cells. Therefore, it will be 
important to understand events at G2M in this respect. A systematic analysis of the 
interaction of mitotic checkpoint proteins with pro and anti-apoptotic molecules 
using shRNA technology for example, would assist in this aim   
Any future work would investigate a possible adjuvant effect of UCN-01 with 
etoposide as my data show that drug resistant cells such as K562 will not die from 
G2. Abolition of this checkpoint induce by low-dose etoposide, by UCN-01 may 
enhance its efficacy. The question then arises as to what effect addition of low-dose 
vincristine would have on UCN-01 manipulated cells treated with etoposide. Would 
etoposide and vincristine then synergise in activating Bax from mitosis? Would 
mitotic checkpoint proteins play a role in this synergy and if so, which ones would 
be required in driving apoptosis. Where would the resistance to apoptosis come 
from in this situation; survivin would be a prime target for investigation. If survivin 
did play a role in resistance to mitotic driven  apoptosis then factors such as its 
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phosphorylation status, its ability to sequester caspase 9, its role in Bcl-2 
phosphorylation and Bcl-2 stabilisation could be investigated (Gascoigne et al, 
2009) 
Other possibilities include the prior manipulation of cells with Aurora B kinase 
inhibitors to de-stabilise survivin; Cdk1 inhibitors such as Roscovitine or Purvanol 
could be investigated in their role in preventing Cdk1 phosphorylation of survivin, 
which also promotes survivin de-stabilisation, as possible sensitizing agents for low-
dose vincristine and/or etoposide induction of  mitotic apoptosis. Roscovitine, 
purvanol and Aurora B inhibitors are currently in clinical trials (Kaestner et al, 
2009). 
New agents will also come on line which disrupt events at mitosis. I would also 
predict that any agent mimicking cyclin A-bound-Cdk1, phosphorylated on tyrosine 
residues not including tyrosine 15 would facilitate mitotic apoptosis.   
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Abbreviations 
ADP                        Adenosine 5’-diphosphate 
ALL                        Acute lymphocytic leukaemia 
AML                       Acute myeloid leukaemia 
Ann V                      Annexin V 
APC/C                    Anaphase Promoting Complex/Cyclosome 
APS                       Ammonium Persulphate 
Ara-C                     Cytosine Arabinoside 
ARF                        Alternative Reading Frame 
Asp                        Aspartate  
ATM                      Ataxia Telangiectasia Mutated 
ATP                      Adenosine 5’-triphosphate 
ATPase                 Adenosine 5’-triphosphate synthase 
ATR                     Ataxia Telangiectasia Related 
BH3                      Bcl-2 homology domain 3 
BIR                      Baculovirus IAP repeat 
BSA                     Bovine Serum Albumin   
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°C                        Degrees Celcius 
Ca2+                     Calcium ions 
CAD                    Caspase-activated deoxyribonuclease 
CAK                    CDK Activating Kinase 
CARD                 Caspase recruitment domain 
Caspase                cysteine aspartate protease 
CDC (cdc)            Cell Division Cycle 
CDK                    Cyclin Dependent Kinase  
CML                   Chronic Myeloid Leukaemia 
CO2                               Carbon Dioxide 
cpm                     Counts per Minute 
C-terminal            Carboxy terminal 
DNA                    Deoxynucleic Acid 
DR                      Death Receptor 
E1                       Ubiquitin activating 
E2                       Ubiquitin conjugating 
E3                       Ubiqutin ligating 
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ECACC               European Collection of Animal Cell Cultures  
ECL                  Enhanced Chemiluminescence   
EDTA                Ethylenediamine tetraacetic acid 
ELISA               Enzyme-Linked Immunosorbant Assay  
FADD                Fas-associated death domain 
FITC                  Fluorescien Isothiocyanate  
G                       Gram 
G0                     Gap 0 
G1                     Gap 1 
G2                     Gap 2 
G2M                  Gap2/Mitosis 
GMCSF              Granulocyte/Macrophage-Colony Stimulating Factor 
HBSS                 Hank’s Balanced Salt Solution  
HCl                    Hydrochloric Acid 
HEPES               N-(2-Hydroxyethyl)piperazine-N’-(2-ethanesulfonic acid) 
HHT                  Homoharringtonine 
HRP                  Horse Raddish Peroxidase 
HTLV-1             Human T cell lymphotrophic virus type 1 
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IAP                   Inhibitor of apoptosis protein 
IL                    Interleukin 
JAK                 Janus Protein Kinase 
kDa                  KiloDalton 
KOH                Potassium Chloride 
L                     Litre  
µg                   Microgram 
µl                    Microlitre 
µm                  Micrometer  
µM                  Micromolar 
M                    Molar 
M                    Mitosis 
MDR               Multidrug Resistance  
mg                  Milligram 
min                 Minute 
ml                   Millilitre 
mM                 Millimolar 
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mm                 Millimeter 
MPF                Mitotic Phase Promoting Factor 
mV                  Millivolts 
ng                    Nanogram  
nm                   Nanometer 
Noc                  Nocodazole 
N-terminal        Amino terminal 
PAG                Polyacrylamide Gel  
PAGE              Polyacrylamide Gel Electrophoresis 
PARP              Poly(ADP-ribose) polymerase 
PBS                Phosphate Buffered Saline  
Ph                   Philadelphia 
PI                    Propidium iodide 
PMSF              PhenylMethaneSulphonyl Fluoride  
PS                    Phosphatydyl serine 
PVDF              Polyvinylidedifluoride  
RB                  Retinoblastoma 
Rf                   Refractive Front  
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RIPA               Radioimmunoprecipitation 
RNA                Ribonucleic Acid 
RNAse             Ribonuclease 
Rpm                Revolutions per Minute 
RPMI               Roswell Park Memorial Institute 
S                       Synthesis 
SAC                  Spindle activation complex 
SDS                 Sodium Dodecyl Sulphate 
Ser                   Serine  
SSC                 Sodium Chloride Sodium Citrate  
STAT               Signal Transducer and Activators of    Transcription 
T                     Threonine 
T14                 Threonine residue 14 
T161               Threonine residue 161 
TBE                tris borate EDTA  
TBS                Tris(hydroxymethyl)aminomethane buffered saline  
TBST              TBS Tween-20®  
TEMED           N,N,N’,N’,-tetramethylethylenediamine 
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Thr                   Threonine 
TNF                Tumour Necrosis Factor 
TNFR             TNF Receptor 
TRADD           TNF-R1-associated death domain 
TRAF              TNF receptor associated factor 
TRAIL             TNFα-related apoptosis-inducing ligand 
tris/Trizma          Tris(hydroxymethyl)Aminomethane 
TRITC               Tetramethylrhodamine Isothiocyanate  
Tyr                     Tyrosine 
Ubq                   Ubiquitin 
V                      Volts 
v/v                    Volume per Volume 
w/v                   Weight per Volume 
Y                      Tyrosine 
Y15                   Tyrosine residue 15 
Y15-P                 Tyrosine residue 15 phosphorylation 
Y-P                    Tyrosine phosphorylation 
Yx                     Tyrosine residue(s) other than Y15 
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9.0 APPENDICES: 
9.1 APPENDIX A. REAGENTS, CHEMICALS AND BUFFER PREPARATION  
9.1.1 Reagents and equipment used for cell culture 
Supplemented RPMI 1640 Medium 
RPMI 1640 medium containing 25mM N-(2-Hydroxyethyl)piperazine-N’-(2-
ethanesulfonic acid) (HEPES) was purchased from Sigma, UK. This was 
supplemented with 10% v/v heat inactivated foetal bovine serum (Sigma, UK), 2mM 
L-glutamine (Sigma, UK), 60 µg/ml sodium benzylpenicillin (Britannia 
Pharmaceuticals Ltd, UK) and 100 µg/ml streptomycin sulphate (Evans Medical Ltd, 
UK).  
 
9.1.2 Reagents used for cryopreservation and replenishment of leukaemic cell lines: 
Cryopreservation Medium  
RPMI 1640 was supplemented with 50% v/v heat inactivated foetal bovine serum 
(Sigma, UK) and 10% v/v dimethylsulphoxide (DMSO) (BDH, UK).  
Chemicals and Equipment for Freezing Cells 
Isopropanol (BDH, UK) was used to fill the Nalgene™ cyro 1°C freezing container. 
 
9.1.3 Reagents used for cell viability testing: 
Trypan Blue Dye Solution  
1 mg of Trypan blue dye (Sigma, UK) was dissolved in 1 ml of HBBS (Sigma, UK) 
and sterilised by passing through a 0.22 µm Millipore filter. This working solution of 
0.1% w/v trypan blue/HBBS was stored at 4°C. 
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9.1.4 Chemotherapeutic and chemical reagents used in experiments: 
Cytarabine 
Etoposide (VP-16) (Vespid) at a concentration of 20, 40 µg/ml was obtained from 
Bristol Myers, UK.  
Nocodazol (Sigma, UK) 10 mg of was dissolved in 1 ml of DMSO (BDH, UK) to 
make a 10 mg/ml stock solution. 
Vincristine 0.02 -80µg/ml 
 
9.1.5 Buffers and reagents used for the analysis of apoptosis by flow cytometry: 
Phosphate Buffered Saline (PBS) pH 7.2  
PBS tablets were purchased from Oxoid, UK. 1 PBS tablets was dissolved in 100 ml 
of deionised water. 
Chemicals Used for Fixing and Staining Cells 
Ethanol (Absolute Alcohol) was purchased from Hayman Ltd, UK 
1 mg RNAse (Sigma, UK) and 250 µg of Propidium Iodide (Sigma, UK) were 
dissolved in 5 ml PBS (Oxoid, UK) 
Annexin V V-FITC (BD Biosciences pharmingen) 5µl per test used. 
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9.1.6 Reagents for mini-agarose gel electrophoresis: 
10× Tris Borate Ethylenediamine tetraacetic acid (TBE) Buffer 
108 g Tris(hydroxymethyl)aminomethane (Tris) (Sigma, UK)  
55 g of boric acid (Sigma, UK) 
40 ml of 0.5M Ethylenediamine tetraacetic acid (EDTA) pH8.0 (Sigma, UK).  
 1 L deionised water. 
1.8% w/v Agarose TBE Gel 
0.63 g of Agarose (Seakem, FMC Bioproducts, Flowgen, UK) was added to 3.5 ml of 
10× TBE buffer which was made to a final volume of 35 ml using deionised water 
this solution was boiled for 1 minute before being cast and allowed to cool.  
 
9.1.7 Reagents for whole cellular lysis: 
RIPA Buffer 
PBS (Oxoid, UK) containing:  
1% v/v Nonidet-P40 (NP40) (Sigma, UK) 
0.5% w/v Sodium Deoxycholate (Sigma, UK)  
0.1% w/v Sodium Dodecyl Sulphate (SDS) (BDH, UK) 
4% v/v aprotinin (Trasylol 10,000 Kallikrein Inactivator Units (KIU)/mL Bayer UK) 
1% v/v Sodium Orthovanadate (0.1M Stock Solution) (Sigma, UK) 
0.5% v/v PhenylMethaneSulphonyl Fluoride (PMSF) (0.1M Stock) (Sigma, UK). 
 
9.1.8 Reagents used in the direct Lowery protein assay method: 
Sigma Protein Assay Kit 
2 mg of freeze dried bovine serum albumin (Sigma, UK) was reconstituted with 5 ml 
of deionised water to make a stock concentration of 400 µg/ml. Protein standards of 0 
µg/ml, 10 µg/ml, 25 µg/ml, 50 µg/ml, 75 µg/ml, 100 µg/ml and 200 µg/ml in a final 
volume of 1 ml were prepared. Modified Lowery reagent (Sigma, UK) (Lowery 
reagent and sodiumdodecylsulfate) was reconstituted with 40 ml deionised water, 
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Folin and Ciocaelteu’s Phenol Reagent (Sigma, UK) was reconsistuted with 90 ml 
deionised water. 
 
 
9.1.9 Reagents used in the preparation of protein for SDS-PAGE electrophoresis: 
Sodium DodecylSulphate (SDS) Loading Dye 
 4 ml deionised water 
 1 ml 0.5M Tris-HCl pH 6.8 (See 9.1.13) 
 800 µl Glycerol (Sigma, UK) 
 1.6 ml 10% w/v SDS (Sigma, UK) 
 400 µl 2 β-Mercaptoethanol (Sigma, UK) 
 200 µl 0.2% w/v Bromophenol blue (Sigma, UK) 
 
 
9.1.10 Reagents for the determination of relative molecular weight: 
Reagents Used in Molecular Weight Determination 
Rainbow™ coloured protein molecular weight markers (Amersham Pharmacia 
Biotech, UK) consist of a mixture of:  
 
 Myosin    220 kDa  
 Phosphorylase b   97 kDa 
 Bovine Serum Albumin 66 kDa  
 Ovalbumin   45 kDa  
 Carbonic Anhydrase  30 kDa  
 Trypsin Inhibitor  20.1 kDa  
 Lysozyme   14.3 kDa   
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9.1.11 Reagents for the preparation of SDS-PAGE mini gels: 
Chemicals Used for SDS-PAGE Gels 
Butanol (Sigma, UK) was mixed in equal volumes with deionised water and the 
solution was shaken to saturate the butanol. The solution was allowed to settle before 
the top layer of saturated butanol was used. 
Buffers Used in the Preparation of SDS-PAGE Gels :     
      1.5M Tris-HCl pH8.8 
      18.17 g Trizma Base (Sigma, UK) was dissolved in 100 ml deionised water, this 
solution was  adjusted to pH 8.8 with Hydrochloric acid (Sigma, UK). 
      0.5M Tris-HCl pH 6.8 
      6.06 g Trizma Base (Sigma, UK) was dissolved in 100 ml deionised water, this 
solution was adjusted to pH 6.8 with Hydrochloric acid (Sigma, UK). 
 
10% SDS-PAGE gels(for detection of  Cyclin A ): 
 4.0 ml Deionised water 
 3.3 ml 30% Acrylamide/bis Acrylamide (Sigma, UK) 
 2.5 ml 1.5M Tris-HCl pH 8.8 
 100 µl 10% w/v SDS (Sigma, UK) 
100 µl 10% w/v APS (Sigma, UK) 
  6 µl TEMED (Sigma, UK)  
12% SDS-PAGE gels (for β-Actin, Bax, Survivin, Aurora B, Tyrosine total, Tyrosin  
15 detection): 
        3.3 ml Deionised water 
        4.0 ml 30% Acrylamide/bis Acrylamide (Sigma, UK) 
        2.5 ml 1.5M Tris-HCl pH 8.8 
        100 µl 10% w/v SDS (Sigma, UK) 
       100 µl 10% w/v APS (Sigma, UK) 
        6 µl TEMED (Sigma, UK) 
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STACK gel: 
 2.7 ml Deionised water 
 0.67 ml 30% Acrylamide/bis Acrylamide (Sigma, UK) 
 0.5 ml 0.5M Tris-HCl pH 6.8 
 40 µl 10% w/v SDS (Sigma, UK) 
    40 µl 10% w/v APS (Sigma, UK) 
     4 µl TEMED (Sigma, UK). 
 
9.1.12 Buffer for the electrophoresis of protein: 
5× Electrode (Running) Buffer 
 7.5 g Tris Base (Sigma, UK) 
 36 g Glycine (Sigma, UK) 
 2.5 g SDS (Sigma, UK) 
500 ml deionised water 
 
1× Electrode buffer was prepared by diluting 100 ml of 5× Electrode buffer with 400 
ml deionised water. 
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9.1.13 Buffer for the electroblotting of protein on to PVDF membranes: 
5× Transfer Buffer 
 7.5 g Tris Base (Sigma, UK) 
 36 g Glycine (Sigma, UK) 
 500 ml deionised water 
1× Transfer buffer was prepared by diluting 100 ml of 5× Transfer buffer with 50 ml 
Methanol (BDH, UK) and 350 ml deionised water. 
 
 
9.1.14 Reagents used for the antibody staining of western blots: 
Tris Buffer Saline pH 8.0 
 100 mM Trizma Base (Sigma, UK) 
 150 mM Sodium Chloride (Sigma, UK) 
This was prepared by dissolving 3.63 g Trizma base and 26.3 g sodium chloride in 3 
L deionised water this was adjusted to pH 8.0 with hydrochloric acid (Sigma, UK) . 
Buffer for Monoclonal Antibodies 
0.05% v/v Tween-20® (Sigma, UK) in TBS (TBST). 
Buffer for Polyclonal Antibodies 
0.1% v/v Tween-20® (Sigma, UK) in TBS (TBST). 
Blocking Solution 
5% w/v dried milk powder (Marvel) in TBST was used to block endogenous 
proteins. 
Optimised Primary Antibody Concentrations: 
β-Actin, mouse monoclonal antibody (Sigma, UK) dilution of 1:40,000 
Bax, rabbit polyclonal antibody  (Santa Cruz, Insight Biotechnology, UK) dilution 
of 1:8,000 
Cyclin A, mouse monoclonal antibody (Santa Cruz, Insight Biotechnology, UK) 
concentration of 2 µg/ml. 
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Phospho-tyrosine15 specific CDK1, rabbit polyclonal antibody (Calbiochem, 
Novabiochem, UK) dilution of 1:1,000. 
Survivin monoclonal antibody (Santa Cruz, Insight Biotechnology, UK) dilution of 
1:5,000. 
Aurora B polyclonal antibody. 
 
Primary (and Secondary) Antibody Incubation Solution 
1% w/v dried milk powder (Marvel) in TBST . 
Optimised Secondary Antibody Concentrations 
Horse Radish Peroxidase (HRP) conjugated Goat anti Mouse (Santa Cruz, Insight 
Biotechnology, UK) dilution of 1:2,000. HRP conjugated Goat anti Rabbit (Santa Cruz, 
Insight Biotechnology, UK) dilution of 1:3,000. 
 
9.1.15 Reagents for the phospho-tyrosine staining of western blots: 
Blocking Solution 
5% w/v BSA (Sigma, UK) in 0.1% v/v Tween-20® (Sigma, UK) in TBS (TBST). 
Optimised Primary Antibody Concentration 
Phospho-tyrosine (HRP conjugated) mouse monoclonal (Upstate Biotechnology, 
Insight Biotechnology, UK) concentration of 0.05 µg/ml. 
Antibody Incubation Solution and Wash Buffer for Phospho-tyrosine Antibody 
0.1% v/v Tween-20® (Sigma, UK) in TBS (TBST). 
 
9.1.16 Reagents for the visualisation of protein bands: 
ECL Reagent  
Supersignal™ CL-HRP Substrate System Kit (Pierce and Warriner, Perbio Science 
UK Ltd) solution A and solution B were mixed together in equal volumes 
immediately prior to use for detection.  
Autoradiography Film  
Hyperfilm® was purchased from Amersham Pharmacia Biotech, UK.  
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 9.1.17  Reagents for the immunoprecipitation of CDK1 and c-ABL: 
Antibody Class Specific Dyna Beads 
1.5×108 Rat anti mouse IgG2a coated Dynabeads® (Dynal, UK) were coated with 15 
µg of CDK1 (cdc2 p34) mouse monoclonal IgG2a antibody. 1.5×108 Sheep anti 
mouse IgG1 Dynabeads® (Dynal, UK) were coated with 15µg of c-ABL mouse 
monoclonal IgG1 antibody. 
Wash Buffer  
0.1% w/v BSA (Sigma, UK) in PBS (Oxoid, UK). 
 
9.1.18 Reagents and buffers for the functional assay of CDK1: 
Kinase Assay Lysis Buffer (for the Immunoprecipitation of Functional Kinases) 
50 mM Tris-HCl pH 7.4 (Sigma, UK) 
250 mM Sodium Chloride (Sigma, UK) 
1 mM EDTA (BDH, UK) 
50 mM Sodium Fluoride (Sigma, UK) 
1 mM DTT (Sigma, UK) 
0.1% v/v Triton® X-100 (Sigma, UK) 
4% v/v aprotinin (Trasylol 10,000 Kallikrein Inactivator Units (KIU)/mL Bayer UK) 
1% v/v Sodium Orthovanadate (0.1M Stock Solution) (Sigma, UK) 
0.5% v/v PMSF (0.1M Stock) (Sigma, UK) 
 
Antibody Class Specific Dyna Beads: 
1.5×108 Sheep anti mouse IgG1 Dynabeads® (Dynal, UK) were coated with 15 µg of 
Cyclin B IgG1 mouse monoclonal antibody.  
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9.2 APPENDIX B. SUPPLIERS OF REAGENTS: 
Reagents, chemicals and equipment used in this study were obtained from the 
following suppliers: 
Alpha Laboratories. Parham Drive, Eastleigh, Hampshire. 
Amersham Pharmacia Biotech Ltd. Amersham Place, Little Chalfont, 
Buckinghamshire. 
Bayer Plc. Bayer House, Strawberry Hill, Newbury, Berkshire. 
BDH Chemical Ltd. Poole, Dorset. 
BD Biosciences pharmingen. Europe. 
Bioquote Ltd. The Raylor Centre, York. 
Boehringer Mannheim UK Ltd. Bell Lane, East Sussex. 
Bristol Myers. Lancaster Place, South Marston Park, Swindon, Wiltshire. 
Britannia Pharmaceuticals Ltd. Redhill, Surrey.  
Calbiochem/Novabiochem (CN Biosciences). Padge Road, Beeston, Nottingham. 
Digital Scientific Ltd. Sheraton House, Castle Park Cambridge. 
Dynal Biotech UK. Croft Business Park, Bromborough, Wirral. 
Evans Medical Ltd. Langhurst, Horsham, West Sussex. 
Fisher Scientific UK Ltd. Bishop Meadow Road, Loughborough, Leicestershire. 
Flowgen. Novara House, Excelsior Road, Ashby de la Zouch, Leicestershire. 
Gibco Lifetechnologies Ltd. Fountain Drive, Inchinnan Business Park, Paisley. 
Hayman Ltd. Eastway Industrial Park, Witham, Essex.  
Insight Biotechnology Ltd. Wembley Middlesex. 
Oxoid, Unipath Ltd. Bassingstoke, Hampshire. 
Perbio Science UK Ltd. Upper Northgate Street, Chester. 
Promega UK Ltd. Delta House, Chilworth Research Centre, Southampton. 
Shandon Scientific Ltd UK. Chadwick Road, Astmoor Runcorn Cheshire. 
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Sigma-Aldrich Chemicals. Gillingham, Dorset. 
Vector Laboratories Ltd. Accent Park, Bakewell Road, Orton Southgate, 
Peterborough. 
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